 
UVA CENTER FOR DIABETES TECHNOLOGY  
 
 
Adapting Diabetes Treatment Expert 
Systems to Patient's Expectations and 
Psychobehavioral Characteristics in Type 1 
Diabetes  
 
 
 
  Protocol Chair  
Marc Breton, PhD   
University of Virginia  
Center for Diabetes Technology  
 Version Number: v 2.0 
05-Oct-2021   
CLINICAL PROTOCOL     
 
 
 
DSS- 2_05- Oct-2021   Page 2 of 82 
 
KEY ROLES  
 
Protocol Principal Investigator   
Name, degree  Marc Breton, Ph.D.  
Institution Name  University of Virginia Center for Diabetes Technology  
  
CLINICAL PROTOCOL     
 
 
 
DSS- 2_05- Oct-2021   Page 3 of 82 
 
PROTOCOL VERSION HISTORY  
Version 
Number  Author(s)  Approver  Effective 
Date  Revision Description  
1.0   24-Apr-2020  Original Protocol  
1.1 Mary Oliveri  Mary Oliveri  20-May -
2020  Added  
• Demographic Data Survey added 
at screening   
1.2 Mary Oliveri   03-Aug-2020  Full Board Revisions:  
• Clarified that par ticipants may 
contact the study team at any 
time during the study to report 
adverse events (Section 5.1.1  
5.3.2, 6.4.3, 6.6.3, 7.6.3).  
• Corrected erroneous sentence  
referencing DHHS 46.405 (section 
10.3).  
• Corrected bullet formatting 
(section 12.3.2).  
• Removed references to Medical 
Monitor throughout protocol.  
• Added references to Data  Safety 
Monitoring Board (section 12.10 ).  
1.3 Jon Olson  Mary Oliveri  08-Nov-2020  Study Team modifications:  
• Physical examination (may use a 
medical record within the past 6 months)  
• Weight, height (participant may 
self-report this information)  
• Vital signs including measurement of blood pressure and pulse (may use a medical record within the past 6 months)  
• Participants will have the option to be given a receiver from the 
study team for medical needs.  
1.4 Jon Olson  Mary Oliveri  22-Jan-2021  DSMB Request : 
• If applicable, subjects will have a 
pregnancy test between phases  
(section 6.4). 
2.0 Mary Oliveri  Marc Breton, Ralf 
Nass  05-Oct-2021  Study Team Modifications:  
• Modified HbA1c limit to HbA1c 6.0-11.0%, inclusive  (section 
3.3
)Edited Sensor Augmented 
Pump Therapy (SAP) to Sensor 
CLINICAL PROTOCOL     
 
 
 
DSS- 2_05- Oct-2021   Page 4 of 82 
 
Augmented Mode (SAM) 
throughout the document  
• Deleted inclusion of carbohydrate 
counting (section 3.3) 
• Added  NPH insulin as study 
exclusion (section 3.4) 
• Added Post -Screening Assessment 
section describing participant  
requirements (section 3.5) 
• Clarified Training visit definition 
(Chapter 4 )Clarified pump and 
MDI training issues  (section 4.1.2, 
4.1.3) 
• Study physician may add up to two 
weeks to CGM run-in period 
(section 5.2.1) 
• Revised Figure 4 and Figure 5 
 
  
CLINICAL PROTOCOL     
 
 
 
DSS- 2_05- Oct-2021   Page 5 of 82 
 
SITE PRINCIPAL INVESTIGATOR STATEMENT OF COMPLIANCE  
Protocol Title:  Adapting Diabetes Treatment Expert Systems to Patient’s Expectations and 
Psychobehavioral Characteristics in Type 1 Diabetes  
Protocol Version/Date: v 2.0/05-Oct-2021  
I have written  the protocol specified above. In my formal capacity as a Site Principal Investigator, 
my duties include ensuring the safety of the study participants enrolled under my supervision. It 
is understood that all information pertaining to the study will be held strictly confidential and 
that this confidentiality requirement applies to all study staff at this site.  
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as required by the following: United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
As the Principal Investigator, I will assure that no deviation from, or changes to the protocol 
will take place without prior agreement from the sponsor and documented approval from the 
Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary 
to eliminate an immediate hazard(s) to the trial participants.  
All key personnel (all individuals responsible for the design and conduct of this trial) have 
completed Human Participants Protection Training and Good Clinical Practice Training. Further, I 
agree to ensure that all staff members involved in the conduct of  this study are informed about 
their obligations in meeting the above commitments.  
 
Investigator’s Signature __________________________________ Date: _____ / _____ / _____  
Investigator’s Name: ________________________________  
Site Name:  University of Virginia  
  
CLINICAL PROTOCOL     
 
 
 
DSS- 2_05- Oct-2021   Page 6 of 82 
 
LIST OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
API Application Programming Interface   
ATI Acceptance and Trust Index  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CR Carbohydrate Ratio  
CLC Closed -Loop Control  
CGM  Continuous Glucose Monitor  
CSII Continuous Subcutaneous Insulin Injection  
CV Coefficient of Variation  
DiAs  Diabetes Assistant  
DCCT  Diabetes Control and Complications Trial  
DKA  Diabetic Ketoacidosis  
DSS Decision Support System  
DWM  DiAs Web Monitoring  
eA1c  Estimated Hemoglobin A1c  
EMA  Ecological Momentary Assessment  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GLM  General L inear Models  
GV Glucose Variability  
HbA1c  Hemoglobin A1c  
HBGI  High Blood Glucose Index  
HTTP  Hypertext Transfer Protocol  
IDE Investigational Device Exemption  
IOB Insulin -on-Board  
ISF Insulin Sensitivity Factor  
JSON  JavaScript Object Notation  
LBGI  Low Blood Glucose Index  
NIH National Institutes of Health  
PF Personalized Feedback  
POC  Point -of-Care  
CLINICAL PROTOCOL     
 
 
 
DSS- 2_05- Oct-2021   Page 7 of 82 
 
QC Quality Control  
QOL  Quality of Life  
REST -ful Representational State Transfer  
SAM  Sensor Augmented Mode  
SAP Sensor -Augmented Pump therapy  
SH Severe Hypoglycemia  
SI Insulin Sensitivity  
SMBG  Self-Monitoring of Blood Glucose  
T1DM  Type 1 Diabetes Mellitus  
T2DM  Type 2 Diabetes Mellitus  
UI User Interface  
URL Uniform Resource Locator  
XML  Extensible Markup Language  
  
CLINICAL PROTOCOL     
 
 
 
DSS- 2_05- Oct-2021   Page 8 of 82 
 
PROTOCOL SUMMARY  
PARTICIPANT AREA DESCRIPTION  
Title  Adapting Diabetes Treatment Expert Systems to Patient’s Expectations and Psychobehavioral 
Characteristics in Type 1 Diabetes  
Investigational Device  CGM -based Personalized Feedback (PF) and Decision Support System (DSS)  
Objectives  Aim 1  (control of GV) We will confirm and contrast the efficacy of two previously designed technological 
interventions – Personalized Feedback (PF) and Decision Support System (DSS) - in reducing glucose 
variability ( GV) in Type 1 Diabetes Mellitus ( T1DM ) during a 6 -month randomized crossover clinical trial.  
Aim 2  (personalization of treatment policy) We hypothesize that the participants in this study will have 
technology intervention preferences (e.g. PF or DSS) that can be predicted by key psychosocial and 
behavioral parameters and are prognostic of the level of GV control achievable by the intervention.  
Aim 3  (monitoring of treatment policy) Finally, we propose to define a novel, measurable, technology 
Acceptance and Trust Index  (ATI) , passively observing and recording user -system interactions, and 
validate this new index using active Ecological Momentary Assessment (EMA) to track user subjective response to DSS.  
Study Design  This is a randomized crossover study in T1DM adults designed to demonstrate the efficacy of 
personalized feedback (PF) and decision support (DSS) over sensor -augmented mode (SAM) therapy and 
to establish relationships between the level of glucose variability (GV) control achievable by the intervention and individual psycho -behavioral characteristics.  
Number of Sites  1 
Outcomes  A key advantage of the proposed study design (beyond the optimal statistical power) is the possibility to 
explore the glucose control and psycho -behavioral impact of features being added and/or enhanced 
with prescriptive components (DSS), vs. features being limited to information (PF) or even removed 
(SAM ).  
Population  Key Inclusion Criteria  
• Age 18 years and older 
• T1DM diagnosis for at least 1 year  
• Established insulin parameters  
Key Exclusion Criteria d 
• Hemoglobin A1c 6.0-11.0%, inclusive  
Sample Size  Enrollment will proceed with the goal of completing 4 cohorts of about 25 participants each (expected 
retention 20 per cohort)  
Treatment Groups  • De-escalation (DSS→PF→ SAM ) 
• Escalation ( SAM →PF→DSS)  
Participant Duration  The study duration for each participant is approximately 7 months.  
Protocol Overview/Synopsis  Four  cohorts of about 25 participants each (expected retention 20 per cohort). Each cohort will continue 
for ~7 months . Following recruitment, screening, and a run- in period of SAM , participants will be 
randomized into one of two groups: escalation vs. de -escalation of devices and function. Each treatment 
modality ( SAM , PF, DSS) will continue for about 8 weeks, with the last 4 weeks used to assess GV from 
CGM data.  
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 9 of 82 
 STUDY VISITS AND PROCEDURES  SCHEDULE  
 Visit 1  
Screening  
and 
Questionnaires  Visit 2  
Study Device 
and 
Procedures 
Training  SAM  
Run-in Visit 3  
Eligibility 
Assessment, 
Randomization  
and Training  DiAs Use 
in Phase 1 
Mode  Visit 4  
Phase 2 
Initiation  DiAs Use 
in Phase 2 
Mode  Visit 5  
Phase 3 
Initiation  DiAs Use 
in Phase 3 
Mode  Visit 6  
Study  
Exit Visit 7 
Post 
Study 
Check in  
Location  Clinic  Clinic  Home  x 
2-4 
weeks  Web 
Conference 
or Clinic  Home x 
8 weeks  Web 
Conference 
or Clinic  Home x 
8 weeks  Web 
Conference 
or Clinic  Home x 
8 weeks  Phone  
or 
Clinic  Phone 
or 
Clinic  
Informed Consent  X           
Medical History  X           
Medications  X           
Physical Exam (including 
vital signs, height/weight)  X           
Pregnancy Test (if 
childbearing potential)  X     X  X    
Blood Testing: TSH, CMP 
(additional labs as 
necessary)  X           
Questionnaires  X  X X X X X X X X  
Equipment Training   X          
DiAs in SAM  Training   X          
Glycemic Treatment 
Guidelines Training   X          
Glucagon Emergency Kit 
Training   X          
Use of DiAs in SAM     X         
Eligibility Assessment     X        
AE Assessment     X  X  X  X  
Randomization     X        
DiAs Phase 1 Mode Training     X        
EMA Training     X        
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 10 of 82  
   Visit 1  
Screening  
and 
Questionnaires  Visit 2  
Study Device 
and 
Procedures 
Training  SAM  
Run-in Visit 3  
Eligibility 
Assessment, 
Randomization  
and Training  DiAs Use 
in Phase 1 
Mode  Visit 4  
Phase 2 
Initiation  DiAs Use 
in Phase 2 
Mode  Visit 5  
Phase 3 
Initiation  DiAs Use 
in Phase 3 
Mode  Visit 6  
Study  
Exit Visit 7 
Post 
Study 
Check in  
 Visit 1  
Screening  
and 
Questionnaires  Visit 2  
Study Device 
and 
Procedures 
Training  SAM  
Run-in Visit 3  
Eligibility 
Assessment, 
Randomization  
and Training  DiAs Use 
in Phase 1 
Mode  Visit 4  
Phase 2 
Initiation  DiAs Use 
in Phase 2 
Mode  Visit 5  
Phase 3 
Initiation  DiAs Use 
in Phase 3 
Mode  Visit 6  
Study  
Exit Visit 7 
Post 
Study 
Check in  
Location  Clinic  Clinic  Home x 
2-4 
weeks  Web 
Conference 
or Clinic  Home x 8 
weeks  Web 
Conference 
or Clinic  Home x 8 
weeks  Web 
Conference 
or Clinic  Home x 8 
weeks  Phone 
or Clinic  Phone 
or Clinic  
Use of DiAs in Phase 1 
Mode      X       
EMA Surveys      X  X  X   
DiAs Phase 2 Mode Training       X      
Use of DiAs in Phase 2 
Mode        X     
DiAs Phase 3 Mode Training         X    
Use of DiAs in Phase 3 
Mode          X   
Review diabetes 
management & AEs     X  X  X  X X 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 11 of 82  
 Table of Contents  1 
 Background  .................................................................................................... 15 2 
1.1. Introduction  .................................................................................................................. 15 3 
1.2. Specific Aims  ................................................................................................................. 23 4 
1.3. Outcomes  ...................................................................................................................... 24 5 
1.4. Study Design .................................................................................................................. 27 6 
1.5. Study Participants  ......................................................................................................... 28 7 
1.6. Clinical Sites  .................................................................................................................. 28 8 
 Study Devices  ................................................................................................. 29 9 
2.
1. Diabetes Assistant (DiAs)  .............................................................................................. 29 10 
2.2. Insulin Pump  ................................................................................................................. 29 11 
2.3. Continuous Glucose Monitor (CGM)  ............................................................................ 29 12 
2.4. Ketone Meter and Strips  ............................................................................................... 29 13 
 Study Screening  .............................................................................................. 30 14 
3.
1. Informed Consent and Authorization Procedures  ........................................................ 30 15 
3.2. Visit 1 - Eligibility Screening Procedures  ....................................................................... 30 16 
3.3. Participant Inclusion Criteria ......................................................................................... 31 17 
3.4. Participant Exclusion Criteria  ........................................................................................ 32 18 
3.5. Post- screening assessments  ......................................................................................... 33 19 
 Training Visit  .................................................................................................. 34 20 
4.
1. Visit 2 - Study Equipment  .............................................................................................. 34 21 
4.2. Ecological Momentary Assessment Training  ................................................................ 36 22 
4.3. Glucagon Emergency Kit  ............................................................................................... 36 23 
 Study Procedures  ........................................................................................... 37 24 
5.
1. Study Contacts  .............................................................................................................. 37 25 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 12 of 82  
 5.2. Sensor -Augmented Mode (SAM) Run -in Period  ........................................................... 37 26 
5.3. Visit 3 – Eligibility Assessment, Randomization and Training  ....................................... 38 27 
 Study Procedures - Escalation ......................................................................... 39  28 
6.2. Sensor Augmented Mode  ............................................................................................. 39 29 
6.3. Home Use of DiAs in Phase 1 Mode  ............................................................................. 39 30 
6.4. Visit 4 – Phase 2 Initiation  ............................................................................................. 40 31 
6.5. Home Use of DiAs in Phase 2 Mode  ............................................................................. 41 32 
6.6. Visit 5 – Phase 3 Initiation  ............................................................................................. 42 33 
6.7. Home Use of DiAs in Phase 3 Mode  ............................................................................. 43 34 
6.8. Visit 6 - Study Exit .......................................................................................................... 43 35 
6.9. Post Study Check -In Visit (Visit 7)  ................................................................................. 44 36 
 Study Procedures – De-Escalation................................................................... 45 37 
7.
1. Randomization to De- Escalation  ................................................................................... 45 38 
7.2. Training on Phase 1 DiAs Mode  .................................................................................... 45 39 
7.3. Home Use of DiAs in Phase 1 Mode  ............................................................................. 46 40 
7.4. Visit 4 – Phase 2 Initiation  ............................................................................................. 46 41 
7.5. Home Use of DiAs in Phase 2 Mode  ............................................................................. 47 42 
7.6. Visit 5 – Phase 3 Initiation  ............................................................................................. 48 43 
7.7. Home Use of DiAs in Phase 3 Mode  ............................................................................. 48 44 
7.8. Visit 6 - Study Exit .......................................................................................................... 49 45 
7.9. Post Study Check -In Visit (Visit 7)  ................................................................................. 50 46 
 Testing Procedures  ......................................................................................... 51 47 
8.
1. Laboratory / Point of Care Testing  ................................................................................ 51 48 
 Questionnaires & Ecological Momentary Analysis  .......................................... 52 49 
9.
1. Diabetes Specific Personality Questionnaire  ................................................................ 52 50 
9.2. ABACUS  ......................................................................................................................... 52 51 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 13 of 82  
 9.3. Diabetes Locus of Control  ............................................................................................. 52 52 
9.4. Confidence in Diabetes Self -Care Scale  ........................................................................ 52 53 
9.5. Clarke's Hypoglycemia Awareness Scale  ...................................................................... 53 54 
9.6. The Diabetes Distress Scale  .......................................................................................... 53 55 
9.7. Hypoglycemia Fear Survey  ............................................................................................ 53 56 
9.8. Hyperglycemia Avoidance Scale  ................................................................................... 53 57 
9.9. Pittsburgh Sleep Quality Index ...................................................................................... 54 58 
9.10.  Technology Acceptance and Expectations Survey (burdens subscale only)  ................ 54 59 
9.11.  INSPIRE (revised for DSS)  .............................................................................................. 54 60 
9.12.  Ecological Momentary Analysis (EMA)  ......................................................................... 54 61 
9.13.  Questionnaire Schedule  ................................................................................................ 56 62 
 Risks, Benefits, and Risk Assessment  .............................................................. 57 63 
10.1.  Potential Risks and Benefits of the Investigational Device  ........................................... 57 64 
10.2.  Potential Benefits  .......................................................................................................... 59 65 
10.3.  Risk Assessment  ............................................................................................................ 59 66 
10.4.  General Considerations ................................................................................................. 59 67 
 Device Cleaning Instructions  ........................................................................... 61 68 
 Adverse Events, Device Issues, and Stopping Rules  ......................................... 62 69 
12.
1. Definitions  ..................................................................................................................... 62 70 
12.2.  Protocol Deviations  ....................................................................................................... 63 71 
12.3.  Reportable Events  ......................................................................................................... 63 72 
12.4.  Relationship of Adverse Event to Study Device  ............................................................ 64 73 
12.5.  Intensity of Adverse Event ............................................................................................ 65 74 
12.6.  Coding of Adverse Events  ............................................................................................. 65 75 
12.7.  Outcome of Adverse Events  ......................................................................................... 65 76 
12.8.  Reportable Device Issues  .............................................................................................. 66 77 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 14 of 82  
 12.9.  Timing of Event Reporting  ............................................................................................ 67 78 
12.10.  Data and Safety Monitoring Board  ............................................................................... 67 79 
12.11.  Stopping Criteria  ........................................................................................................... 68 80 
12.12.  Independent Safety Oversight  ...................................................................................... 68 81 
 Miscellaneous Considerations  ........................................................................ 69  82 
13.1.  Prohibited Medications, Treatments, and Procedures ................................................. 69 83 
13.2.  Participant Withdrawal  ................................................................................................. 69 84 
13.3.  Confidentiality  ............................................................................................................... 69 85 
 Statistical Consideration  ................................................................................. 70 86 
14.
1. Design and Randomization  ........................................................................................... 70 87 
14.2.  Sample Size  ................................................................................................................... 70 88 
14.3.  Outcome Measures  ....................................................................................................... 71 89 
14.4.  Exploration of the effect of treatment escalation vs. de -escalation  ............................ 72 90 
14.5.  Psychological and Behavioral Questionnaires  .............................................................. 72 91 
14.6.  Baseline Descriptive Statistics ....................................................................................... 72 92 
14.7.  Device Issues  ................................................................................................................. 72 93 
 Data Collection and Monitoring  ...................................................................... 73 94 
15.
1. Case Report Forms and Device Data  ............................................................................. 73 95 
15.2.  Study Records Retention  .............................................................................................. 73 96 
 Ethics/Protection of Human Participants  ........................................................ 74 97 
16.
1. Ethics Standard  ............................................................................................................. 74 98 
16.2.  Institutional Review Boards  .......................................................................................... 74 99 
16.3.  Informed Consent Procedures and Documentation  ..................................................... 74 100 
16.4.  Participant and Data Confidentiality ............................................................................. 74 101 
 References  ..................................................................................................... 76 102 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 15 of 82  
  103 
 104 
 Background  105 
 
 106 
1.1.1.  Significance  107 
Type 1 diabetes mellitus (T1DM) is an autoimmune condition resulting in absolute insulin 108 
deficiency and a life -long need for insulin replacement  [1]. Glycemic control in T1DM remains a 109 
challenge, despite the availability of modern insulin analogs [ 2], the improving accuracy of 110 
glucose monitoring [ 3-4], and the widening use of intensive insulin therapy. While new 111 
technologies have proven benefits in avoiding diabetes related complications [5] and may have 112 
reduced excess mortality in some populations [6], excess mortality and complication rates remain 113 
significantly higher in T1DM when compared to the general population [ 7-8]. 114 
Glucose variability (GV) in T1DM  is typically at the root of clinicians’ inability to safely achieve 115 
near -normal average glycemia, as reflected by hemoglobin A1c (HbA1c) [ 9]. While target HbA1c 116 
values of 7% or less result in decreased risk of micro - and macrovascular complications [ 10-13], 117 
the risk for severe hypoglycemia ( SH) increases with tightening glycemic control [ 14-16]. 118 
Consequently, hypoglycemia has been implicated as the primary barrier to optimal control [ 17- 119 
18]. Thus, individuals with T1DM face a life -long optimization challenge: reduce average glucose 120 
levels and postprandial hyperglycemia while simultaneously avoiding hypoglycemia. A strategy 121 
for achieving such an optimization can only be effective if it reduces GV. This is because bringing 122 
average glycemia down is only possible if GV is constrained – otherwise blood glucose (BG) 123 
fluctuations would inevitably enter the range of hypoglycemia. However, averages and HbA1c 124 
fail to capture GV and the attendant risks associated with extremes of hypo - and hyperglycemia. 125 
Indeed, in addition to establishing HbA1c as the gold standard for average glycemic control, the 126 
Diabetes Control and Complications Trial ( DCCT ) concluded that: “HbA1c is not the most 127 
complete expression of the degree of glycemia. Other features of diabetic glucose control, which 128 
are not reflected by HbA1c, may add to, or modify the risk of complications. For example, “the 129 
risk of complications may be highly dependent on the extent of postprandial glycemic excursions” 130 
[19]. Thus, more recent studies increasingly focused on the variability of BG fluctuations as an 131 
independent risk factor for diabetes complications [ 9, 20-21], particularly cardiovascular disease 132 
[22-25]. 133 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 16 of 82  
 Intensive insulin therapy : Introduced in the 1980s, intensive insulin treatment by multiple daily 134 
injections (MDI) or use of continuous subcutaneous insulin infusion (CSII), typically includes basal 135 
insulin administered to cover the overnight and fasting periods and bolus insulin given with meals 136 
to cover carbohydrate consumption and to correct postprandial hyperglycemia, in an attempt to 137 
mimic insulin secretion in health [ 26]. Advanced insulin therapy relies on key individual 138 
parameters such as basal rate, carbohydrate ratio  (CR) and  insulin sensitivity factor  (ISF)  [26].  139 
Evidence -based resources are available to patients to control their insulin intake and schedules, 140 
and clinicians to initiate and maintain CSII therapy by selecting appropriate basal rates, 141 
carbohydrate ratios , and insulin sensitivity factor patt erns [ 27].  142 
Expert systems and Control of Glucose Variability:  Periodic adjustments of basal rate, CR , and ISF  143 
patterns are needed based on review of self -monitoring blood glucose (SMBG) profiles, or 144 
continuous glucose monitoring (CGM). If a pattern is identified, optimized insulin dosing 145 
parameters are calculated and implemented. This can be a time -consuming and onerous task, 146 
requiring data to be downloaded from multiple devices and often subjectively evaluated. 147 
Information technology is increasingly playing a positive role in improving the management of 148 
chronic conditions [ 28-29], including diabetes [ 30]. For example, in T1DM, telemedicine and 149 
online patient support has shown promising results [ 31-32]; and retrospectively linking behavior 150 
to glycemic outcomes has proven effective as well [ 33]. With improvements in SMBG and CGM 151 
technologies, a growing appreciation of the quantitative (algorithmic) aspect of the management 152 
of T1DM has led to new tools for remote patient monitoring, data aggregation and visualization 153 
[34]. Early research has developed algorithms for titrating individual insulin treatment 154 
parameters, including iterative learning approaches such as ‘run- to-run’ with structured SMBG 155 
[35-39]. Insulin titration and dosing tools for type 2 diabetes are beginning to enter the 156 
marketplace [ 40], mostly using SMBG. Today, researchers are actively working on CGM -based 157 
decision support for T1DM [ 26, 41-44], capable of providing specific feedback to the clinician 158 
regarding suggested therapy changes. These expert systems have the potential to streamline 159 
clinic visits and facilitate collaborative patient- centered interactions, but in their most advanced 160 
form, they deliver advice directly to the patient [ 41], reducing burden and uncertainty when 161 
making self -management decisions.  162 
Automated Insulin Delivery:  Closed loop control (CLC) technology (i.e. artificial pancreas or AP), 163 
involve s the pairing of CGM with CSII (insulin pump) via a closed loop control algorithm which 164 
automatically adjusts insulin infusion in real- time [ 45]. In the past decade, AP studies have 165 
advanced from short -term inpatient studies [ 46], to long -term clinical trials in free -living 166 
conditions using wearable wireless automated AP systems [ 47]. Our AP studies have enrolled 167 
>450 T1DM patients, who used our smartphone -based system for over 280,000 hours.  168 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 17 of 82  
 Algorithmic advances and computational platforms from these efforts are at the core of this 169 
investigation . 170 
Smartphone based data acquisition and advice delivery platforms:  This investigation  brings 171 
together two key pieces of mobile technology to advance T1DM treatment: The Diabetes 172 
Assistant (DiAs) and Ecological Momentary Assessment ( EMA ). 173 
Diabetes Assistant (DiAs):  The Diabetes Assistant (DiAs) 174 
[48-49] platform is a smartphone- based, modular, 175 
portable device developed at the University of Virginia 176 
(UVa), in collaboration with the University of Montpellier 177 
(Figure 1 ).  DiAs operates on a commercial phone, using a 178 
specifically modified Android operating system, to enable 179 
wireless communication with satellite devices like insulin 180 
pumps, CGMs, and any medical device using a standard 181 
wireless protocol like BT or BTLE. Its modular architecture 182 
allows different control modules to be swapped in real 183 
time, enabling either automated control (CLC) or expert - 184 
decision sup port systems. The DiAs platform also 185 
integrates automated data transfer to a secured server, 186 
enabling cloud functionalities such as remote monitoring 187 
and patient specific adaptation of treatment [ 50]. DiAs is 188 
filed with the FDA (MAF 2109) and has been approved for 189 
use by adults, adolescents, and children with T1DM in 190 
over 20 clinical trials. DiAs is a powerful computation platform that enables both local control of 191 
insulin and cloud applications; it is the most advanced research glucose control platform to date 192 
and has been deployed for months in home CLC trials. DiAs enables the seamless integration and 193 
sequential development of modular decision support systems in a form factor assessed by focus 194 
groups to be acceptable by people with T1DM.   195 
Leveraging EMA  to assess user’s subjective reactions to the decision support system will enable 196 
the first study with such detailed and dynamic investigation of daily trust levels, psychological, 197 
and behavioral responses.  198 
Remote computation and cloud analytics:  DiAs is capable of real- time data transmission to secure 199 
remote servers: the DiAs Web Monitoring (DWM) is a suite of functionalities located on a secure 200 
server within the UVA Health System network. At its core is a database that receives real -time 201 
data about the DiAs status, such as CGM, insulin delivered, connectivity status, and algorithm 202 
status. The system is equipped with a dedicated interface to allow for third party applications to 203 •  
 
 
Figure 1: The DiAs system, a mobile Glucose 
control platform  
 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 18 of 82  
 access data stored on the  DWM server.  It relies on the HTTP protocol and a Representational 204 
State Transfer (REST -ful) architecture to provide  authenticated users with access to the content 205 
of the database, formatted as JSON or XML. The API uses a  URL-based system of requests to 206 
target and filter the  data sent to the client. Several systems are already connected to DWM  [50- 207 
52]. 208 
Impact of technology trust and acceptance in glycemic control:  Trust must be earned; it cannot 209 
be assumed. The concept of trust plays an important role in an individual’s willingness to engage 210 
in the use of a medical device.  In its basic definition ‘trust is to depend or rely on another’ [ 53]. 211 
The “other” can be another person or a device. Trust and acceptance incorporate several key 212 
constructs i.e. confidence versus fear, satisfaction versus burden, distress versus improved 213 
quality of life. Additional factors include perceived usefulness, cost -benefit balance, perceived 214 
ease of use, or impact on others as well as oneself (positive and negative) [ 54-55].   215 
Human factors research indicates that such psychosocial variables play an important role when 216 
it comes to technology uptake. In CGM, factors predictive of uptake and effectiveness, include 217 
perceived system reliability and ease -of-use [ 53,56]. P rior CLC research has also shown that 218 
clinical trials participants were quick to trust a novel device (CGM, CSII and algorithm), sacrificing 219 
personal control over diabetes management to the system, whilst a negative experience impeded 220 
trust, contributing to discontinued use. Other studies of CLC systems have found that, when users 221 
lack trust, they tend to override the devices, while users who report trust in the system 222 
experience decreases in diabetes burden and stress [ 57]. In general, trust is associated with 223 
positive glycemic outcomes and improved psychosocial functioning and quality of life (QOL) [ 58]. 224 
Barriers to trust and continued acceptance include frustration felt when expectations of the 225 
system are not met; feelings of being overwhelmed by the amount of information provided, or 226 
negative reactions from the social environment e.g. diabetes -related stigma, possibly resulting in 227 
a perceived need to explain/justify why a technical device is worn constantly on the body [ 53]. In 228 
addition to patients’ perceptions rooted in their previous experience, unrealistic expectations 229 
may lead to disappointment and discontinuation of the device.  230 
General ‘tech savviness’ can also play a role in acceptance in that those more familiar and 231 
comfortable with technology may be more willing to trust the system. Furthermore, the time and 232 
effort required to invest in building device -related skills, trust and acceptance may be 233 
underestimated (and often is), as these range from technical handling to integrating the system 234 
information into one’s diabetes self -management and everyday living without intrusive 235 
disruptions. Therefore, psychological and behavioral factors play a critical role in the acceptance 236 
of diabetes technologies and the trust patients put in them. It is crucial to determine the 237 
psychosocial and behavioral predictors to uptake and continued use of technology in order to aid 238 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 19 of 82  
 identification of those individuals most likely to realize benefits of any intervention as well as 239 
those individuals who may require more support to succeed with technology. Additional 240 
individual patient’s characteristics (e.g. diabetes belief systems and self -management skills) may 241 
be predictive of technology acceptance, trust, use, and benefit. At present, little is known about 242 
psychological, behavioral and social factors that contribute to diabetes technology adoption and 243 
successful use.  244 
This investigation  will determine psychosocial and behavioral predictors of intervention efficacy, 245 
providing data and psychological techniques to support future onboarding and successful use of 246 
the DSS, as well as validate novel mechanisms to track trust and acceptance, allowing future 247 
systems to adapt to the user’s need s, minimizing potential burden and lifestyle interference, and 248 
ensuing individualized, person- centered support for optimal glycemic and psychosocial/quality 249 
of life outcomes.  250 
Hypothesis:  We hypothesize that psycho -behavioral factors are likely to influence system 251 
acceptance and trust, and ultimately the patients’ success in leveraging the device to achieve 252 
their individual goals, e.g. better glycemic control with similar burden, or lower treatment burden 253 
with similar glycemic control. To our knowledge, no technological intervention has been assessed 254 
in terms of which mode of advice or information delivery is most appropriate to a patient’s 255 
unique characteristics. Thus, the proposed study is the first to map key psycho -behavioral factors 256 
to the expert system characteristics that are most beneficial for treatment success.  257 
Tracking and Quantifying User/System Interactions:  This study merges the expert platform 258 
(DiAs) with software designed to detect, record, and contextualize the interactions between the 259 
patient and a medical device. This unique combination of established mobile diabetes technology 260 
and cutting -edge software previously unrelated to diabetes, will allow: (i) systematically record 261 
treatment behaviors; (ii) track user/system interactions, and (iii) accurately quantify the resulting 262 
glucose control. The new DiAs -EMA system  is a k ey innovation and a new tool enabling us to 263 
study the interplay of technology, behavior, and treatment of diabetes.  264 
Using a tracking system, the investigators will be able to observe each user of the system; this in 265 
turn allows for an internal quantification of the user level of trust and acceptance and its time 266 
course.  267 
Modular Design of Decision Support Systems:  The AP and diabetes expert systems are 268 
assembled from independent (but compatible) modules, each performing a specific control or 269 
diagnostic function, e.g. prevention of hypoglycemia or postprandial insulin corrections [ 59-60]. 270 
This architecture allowed for sequential testing and clinical deployment of AP and DSS 271 
components and provided a structured framework for networks of control systems  [60]. This 272 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 20 of 82  
 architecture is fundamental to the goals of this project: we plan to further refine and evaluate a 273 
layered glucose variability control system activating different modules depending on the stage of 274 
the proposed study ( PF vs DSS). Moreover, a modular system is inherently capable of graceful 275 
degradation -the capacity to ensure safety even if a module fails. Eventually, this architecture 276 
would allow the system to adapt its function to maximize system use and adherence, sequentially 277 
enabling more advanced functions as patients build trust and integrate DSS in their treatment. 278 
The modules to be included in the PF  and DSS have been validated in human clinical trials (see  279 
1.1.2 Preliminary Data). These modules include:  280 
• CGM value, trace, and threshold alarms (applicable to SAM  & PF & DSS):  Similar to 281 
commercial real -time CGM (e.g. Dexcom G6), this module informs the user of the current 282 
glucose level and how it has changed recently, enabling treatment decisions. Alerts are set by 283 
the user to trigger if BG leaves a preset range.  284 
• Hypoglycemia Risk Indicator (PF & DSS):  Based on our group’s work in the  1990s and the 285 
definition of the glycemic risk ranges [ 61], we have developed short (1 -3 hours), medium (1 -3 286 
days), and long (1 -3 weeks) term hypoglycemia risk indices. Prototypes of these modules have 287 
been evaluated clinically (see Preliminary Data).  288 
• Insulin Sensitivity Profile & Indicator ( PF & DSS):  We have designed an algorithm capable of 289 
tracking changes in insulin sensitivity (SI) and creating daily and monthly SI profiles [ 62]. We 290 
additionally validated a real- time SI indicator to inform insulin dosing (e.g. is the patient more 291 
or less sensitive than usual?)  [41].  292 
• Insulin on Board ( PF & DSS ): IOB is a key index to avoid insulin stacking and is available to DiAs 293 
through its insulin pump connectivity. DiAs uses a common 4 -6 hours action curve derived 294 
from encoparesis study  [63]. 295 
• Exercise Advice (DSS): From our modeling work [ 64], we have derived an advisory module that 296 
ensures safety of mild to moderate exercise by predicting whether an exercise bout is likely to 297 
result in hypoglycemia and providing a graded carbohydrate supplementation strategy. See 298 
clinical validation in  [64]. 299 
• Bedtime Advice (DSS):  Similar to the Exercise advisor, this module uses logistic regression and 300 
recent data (CGM, insulin and meals) to gauge overnight hypoglycemia risk and provide 301 
bedtime carbohydrate advice.  302 
• Smart Bolus Calculator ( DSS):  DSS supports advanced bolus calculation capable of accounting 303 
for several GV factors such  as metabolic characteristics (correction based on 45  min predicted 304 
glucose to account for insulin delays) and SI fluctuations (insulin sensitivity tracker).  305 
• Automated Treatment Parameter Optimization (DSS):  Based on replay simulation technology 306 
[42], this optimization routine analyzes the previous 30 days of CGM, insulin, and meal data to 307 
provide updated insulin treatment parameters (CR, I SF). 308 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 21 of 82  
 1.1.2.  Preliminary Data  309 
SMBG Information- Based 310 
Decision Support (PF, 2006 - 311 
11): We have shown that 312 
automated behavioral 313 
feedback delivered in the field 314 
by a portable device can 315 
optimize glycemic control by 316 
reducing HbA1c and/or 317 
occurrence of severe 318 
hypoglycemia [ 33]. We tested 319 
the effect of an automated 320 
system providing real -time 321 
estimates of HbA1c, glucose 322 
variability, and risk for 323 
hypoglycemia. For 10 months, 324 
120 adults with T1DM, 325 
performed SMBG and received 326 
feedback  at three increasingly  327 
complex levels (3 months, each): (i) routine SMBG; (ii) estimated HbA1c, hypo risk, and glucose 328 
variability; (iii) estimates of symptoms potentially related to hypoglycemia. HbA1c, and 329 
hypoglycemia were evaluated at baseline and at the end of each level. This information -based 330 
decision -support reduced HbA1c from 8.0 to 7.6%, p=0.001 (effect confined to subjects with 331 
baseline HbA1c above 8.0. Incidence of symptomatic moderate/  severe hypoglycemia was 332 
reduced from 5.72 to 3.74 episodes/person per month (p=0.019), more prominently for subjects 333 
with history of SH or hypoglycemia unaw are (Figure 2 ). We therefore concluded that feedback of 334 
SMBG data and summary SMBG -based measures can result in improvement in average glycemic 335 
control and reduction in moderate/severe hypoglycemia [ 33]. The system used in this study was 336 
an early prototype of the PF developed  here but leveraging only SMBG data [ 33]. This 337 
technological limitation necessitated manual input of high measurement frequencies (4 -10 338 
SMBG per day). This investigation  leverages automatically collected high frequency CGM data to 339 
further improve the usability of the PF  system, as well as comparing the effect and acceptability 340 
of DSS to more prescriptive features.  341 
Pilot study of Decision Support (DSS, 2012 -2017):  The feasibility and safety of a prototype DSS 342 
was tested in 15 women and 9 men with T1DM on insulin pump (N=16) or MDI (N=8), 343  
Figure 2: Results from 1 -year automated decision -support intervention 
based on SMBG data, with 3 levels of feedback to the patient  
    
 5678910
Baseline Level 1 Level 2 Level 3
Baseline A1c < 8.0 Baseline A1c >= 8.0A: HbA1c Throughout the Study
00.10.20.30.40.5
Baseline Level 1 Level 2 Level 3
No history of SH History of SHB: Severe Hypoglycemia
(episodes/subject/month)
P=0.001
P<0.005 n.s.P<0.001
n.s. P<0.05
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 22 of 82  
 [STUDY_ID_REMOVED]. Age was 37±11 years old, average T1DM duration was 21±11 years. Participants 344 
were well controlled on average (HbA1c of 7.2±1%). Participants followed a non -blinded 345 
randomized crossover design, with two 48 -hours observation periods where patients were 346 
exposed to a variety of meals and physical activities to challenge their own control strategies and 347 
the DSS. DSS  was shown to be feasible and safe (no adverse events). Furthermore, GV was 348 
significantly improved (primary outcome, CGM coefficient of variation) from 0.36±0.08 during 349 
standard of care to 0.33±0.06 using DSS, p=0.045, with maximum effect  during daytime. Further 350 
GV analysis using the Low and High blood glucose indices (LBGI, HBGI, [ 65]), confirmed that most 351 
of the observed improvement was due to the hypoglycemia -related GV measured by the LBGI: 352 
2.5±2.1 to 1.6±1.3, p=0.042. As depicted in ( Figure 3 ), protection from hypoglycemia was 353 
improved significantly while using the DSS: median percent time spent below 70mg/dL was 354 
reduced 3.5 -fold, from 3.2% to 0.9%, p=0.018, while maintaining average glycemia 155±27mg/dL 355 
vs. 155±23mg/dL, p=0.86.  [41] 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
Ecological Momentary Analysis (EMA) : Our research group has a long and prolific history in the 366 
use of EMA to study associations between glycemic parameters and psychosocial and behavioral 367 
variables. Our original EMA studies were  conducted in the 1980s using pen and paper 368 
questionnaires completed just before SMBG, 3 -5/day over several weeks. We investigated 369 
numerous aspects of living with T1D, including idiosyncratic symptoms associated with BG 370 
fluctuations [ 66-67 ], patient ability to recognize hypo - and hyperglycemia [ 68-69], adherence to 371 
SMBG recommendations, and relationships between BG extremes and mood state [ 70-71]. In the 372 
1990s handheld personal computer technology replaced paper for the collection and storage of 373 
more complex daily diary data with date & time stamps. This technological advance allowed us 374 
to investigate relationships between diabetes self -management behaviors and BG patterns, as 375 
well as treatment decision -making (e.g. to drive or not when BG is low) [ 72-75]. 376 
 
Figure 3: Impact of DSS on exposure to hypoglycemia and average glucose. 
Control (grey dots and envelop) and Treatment (black dot and dark grey 
envelop) are linked by the dotted line for each subject.  
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 23 of 82  
 As technology continued to advance, we were able to program daily diaries to include, not only 377 
questionnaires, but also brief cognitive tasks, which could be timed and scored. In a series of 378 
studies in the early 2000s [76- 79], our group utilized PDAs to investigate cognitive performance 379 
in real -world settings at different BG levels in adults with T1DM and T2D M [77] and school -aged 380 
children [ 79]. Additionally, we conducted studies exploring the relationships between glycemic 381 
fluctuations and symptoms/moods in patients with T2D M [76] and the ability of young children 382 
and their parents to recognize hypoglycemia [ 78]. Leading to our first DSS system. 383 
Over the past few years, our group has combined EMA approaches with CGM data collection in 384 
innovative ways to address clinically important questions regarding relationships between BG 385 
levels and behavioral variables, such as the association between psychological stress and BG 386 
patterns using CLC algorithms [ 80]; where we found a small but significant association between 387 
stress and glycemic instability. In 2017, we used the EMA approach in a study of the accuracy of 388 
Diabetes Alert Dogs, comparing daily diaries of dog alerts to blinded CGM data [ 81-82]. That study 389 
documented that accuracy at detecting hypoglycemia was highly variable across individual dogs 390 
and highlighted the need for standardized training and performance. Most recently, our team 391 
has completed a clinical trial using EMAs in a sample of older adults (age > 65) and children with 392 
T1DM to assess the cognitive impact of CLC; the data collection process was a success , but the 393 
analysis is still undergoing,  and we expect to publish t hese results  by the end of 2020. In addition 394 
to the above studies, our group also has a long history of using EMA approaches to collect pre - 395 
and post -intervention data in clinical trials of behavioral interventions [ 66-69], as proposed here. 396 
Taken together, there is ample evidence of our group’s experience and expertise with research 397 
using EMA methods.  398 
Based on these pilot results, we propose to move forward with demonstrating the superior 399 
efficacy of a CGM- based advisory system in T1DM, as compared to SAM , and with characterizing 400 
the impact of psycho- behavioral factors on system performance, which will enable system 401 
individualization and lead to automated adaptation of advice delivery to optimize glycemic 402 
control and reduce the system’s psychological impact.  403 
 
 404 
Aim 1 ( Control of Glucose Variability ) We will confirm and contrast the efficacy of two previously 405 
designed technological interventions – Personalized Feedback (PF) and Decision Support System 406 
(DSS) - in reducing GV in T1DM during a 6 -month randomized crossover clinical trial. This will 407 
allow us to show:  408 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 24 of 82  
 Aim 1.1 the superiority of the PF over Sensor -augmented mode  (SAM ) in controlling GV. PF is a 409 
system designed to provide patients with actionable information about glucose control in general 410 
and GV in particular (e.g. estimated HbA1c (eA1c), risk of hypoglycemia, and activity level);  411 
Aim 1.2 the superiority of the DSS over SAM  in controlling GV. DSS is a CGM -based system that 412 
includes PF and further assists with treatment recommendations for common metabolic 413 
challenges;  414 
Aim 1.3 the overall non -inferiority of DSS over PF intervention to control GV and superiority of 415 
DSS to maintain tight glycemic control over time (lower variations of GV in time).  416 
Aim 2 (personalization of treatment policy)  We hypothesize that the participants in this study 417 
will have technology intervention preferences (e.g. PF or DSS) that can be predicted by key 418 
psychosocial and behavioral parameters and are prognostic of the level of GV control achievable 419 
by the intervention. We will:  420 
Aim 2.1 confirm that technology acceptance and trust are predictive of the level of GV control 421 
achieved during the study (see Aim 1), regardless of the type of DSS system in use. We 422 
hypothesize that technology acceptance will correlate negatively with GV: i.e. higher technology 423 
acceptance leads to lower GV;  424 
Aim 2.2 explore the impact of technology expectations and experience on the performance of 425 
each type of technology intervention ( SAM , PF, DSS). For example, higher expectation will 426 
negatively correlate with GV for the SAM  treatment, but not the DSS treatment.  427 
Aim 2.3 assess the correlation between relevant psycho -behavioral traits with the performance 428 
of PF vs DSS, identifying potential pathways to the corresponding optimal technology- based 429 
treatment policies.  430 
 
 431 
 Glycemic outcomes 432 
The primary outcome of this study will be Glucose Variability (GV) as measured by CGM- based 433 
Coefficient of Variation (CV), as recommended by the International Consensus on Use of 434 
Continuous Glucose Monitoring. To further characterize glucose control, we will compute other 435 
CGM Consensus outcomes as well:   436 
Average   437 
Percent in different ranges:   438 
o <50 mg/dL   439 
o <54 mg/dL   440 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 25 of 82  
 o <60 mg/dL   441 
o <70 mg/dL   442 
o ≤70-≤180 mg/dL   443 
o >180 mg/dL   444 
o >250 mg/dL   445 
o >300 mg/dL   446 
 447 
Each modality of treatment will be assessed using the last 4 weeks of CGM recordings, as we 448 
expect most of the GV benefits of each intervention to be realized within the first 4 weeks of the 449 
intervention, and a minimum of 24 days of data is considered optimal for CGM –based CV 450 
determination.  451 
1.3.2.  Glucose Variability Reduction Achieved with CGM -based expert systems  452 
General linear models (GLM) (repeated measures ANOVA) will be used to assess the significance 453 
of the differences in average response between SAM , PF, and DSS across appropriate CGM -based 454 
metrics. The particular design of the clinical study allow for Aims 1.1, 1.2, and 1.3 to each be 455 
addressed independently in a randomized crossover analysis, as shown in Figure 4 . While the 456 
randomized order of the interventions (escalation vs de -escalation) allows for an objective 457 
assessment of the average efficacy of each of them, we will introduce the order as a fixed factor 458 
to verify if significant study effects can be detected. Finally, we will study the evolution of GV 459 
within each modality period: GV and other CGM -based outcomes will be computed bi -weekly 460 
(the minimum length of time for precise GV assessment) and entered in a repeated measures 461 
GLM analysis; within -subject contrast (linear and polynomial) using 5 repeated measures per 462 
condition to explore the evolution of the glycemic outcomes in time; Aim 1.3 .  463 
 464 
Figure 4:  Multiple analyses enabled by study design to address Aim 1.1, 1.2 and 1.3  465 

CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 26 of 82  
 1.3.3.  Exploration of the effect of treatment escalation vs. de- escalation   466 
A key advantage of the proposed study design (beyond the optimal statistical power) is the 467 
possibility to explore the glucose control and psycho -behavioral impact of features being added 468 
and/or enhanced with prescriptive components (DSS), vs. features being limited to information 469 
(PF) or even removed ( SAM ). We will perform this analysis by looking at the between factors in 470 
the repeated ANOVA analysis, contrasting the escalation group vs. de -escalation group. While 471 
not powered, this analysis will provide key insights in the future feature adaptation schemes 472 
based on the ATI.  473 
1.3.4.  Psychological and Behavioral Questionnaires  474 
As part of Aim 2, we will conduct robust psychosocial analyses of factors important to participant 475 
experience. This will examine relevant core constructs of trust, acceptance, satisfaction, 476 
confidence as well as fear, worries, distress and burden. Validated and reliable measures will be 477 
used to explore psycho -behavioral characteristics and outcomes in addition to specifically 478 
adapted measures for SAM  and DSS technologies to capture holistic, disease -specific and 479 
technology -specific data. These questionnaires will evaluate how specific constructs are 480 
predictive of successful glycemic outcomes associated with DSS. These questionnaires will enable 481 
us to assess important non- glycemic treatment outcomes that are meaningful to patients 482 
including those affecting Quality of Life (QOL) (e.g. fear of hypoglycemia and diabetes distress). 483 
To those ends, participants will complete a battery of questionnaires related to diabetes 484 
management, treatment satisfaction and QOL at baseline (before system use) and after each 485 
treatment modality.  486 
1.3.5.  Ecological Momentary Assessment  Data Collection  487 
Participants will be trained on the EMA surveys and requirements. During each treatment 488 
condition,  over the course of  2-3 days  every two weeks,  the participant will be asked to complete 489 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 490 
participant during each Phase. The DiAs phone will display a text message containing a link to the 491 
survey. Surveys will be triggered at fixed times, including a morning survey ~1h after waking up 492 
and an end -of-the-day survey around 8 -9 PM. Participants will be able to delay (up to 30 min) or 493 
skip (up to 2 per day excluding at wake up) surveys for their convenience.  Participants will 494 
respond to questions on a 5 -point Likert scale (0=Not at All, 4=Extremely). The first Diary for each 495 
day will contain two additional items for rating sleep quantity/quality. The Daily Diary questions 496 
are intended to assess agreement, trust , treatment satisfaction, diabetes burden, self- efficacy, 497 
mood valence, energy level, physical well -being, and concerns about hypo - and hyperglycemia. 498 
The first Diary for each day will contain two additional items for rating sleep quantity/quality.  499 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 27 of 82  
 1.3.6.  Mapping of Psycho -behavioral Characteristics to DSS Preferences and Performance  500 
Baseline assessments of psycho -behavioral traits will be introduced as covariates in the general 501 
linear model when analyzing the glycemic performance of each treatment modality ( SAM , PF, 502 
DSS). Contrasts will be used to study each pair, specifically SAM  vs any advisory system. For 503 
constructs that can be changed by the intervention itself (e.g. Fear of hypoglycemia) and that are 504 
therefore measured after each intervention, we will use repeated measures model with within - 505 
subject covariates (MIXED models) to understand their impact on DSS efficacy. This analysis will 506 
shed light on the relationship between the efficacy of treatment modality and individual patient 507 
characteristics;  Aims 2.1 and 2.2  508 
Using the cloud  data system, we will isolate patient -system interactions for each advisory module 509 
(e.g. eA1c,  predictive hypoglycemia  alert), and compute for each subject the probability of the 510 
interaction to lead to the expected action, and positive glycemic outcomes. These probabilities 511 
will then be used as outcome variables in separate analysis to assess whether psycho -behavioral 512 
traits are associated with the acceptance of specific advisory functionalities (e.g. Fear of 513 
Hypoglycemia could be lowered by the hypoglycemia prediction module); answering Aim 2.3.  514 
1.3.7.  Identification and Validation of the Acceptance & T rust Index  515 
Finally, we will use the validated trust and acceptance measures obtained throughout the 516 
protocol to validate the dynamic tracking of ATI. The 80 studied subjects will be divided in 4 517 
cohorts of 20, the  first 3 groups used to iteratively refine our estimation procedure (interaction 518 
quantification and dynamical model parameters) to accurately reproduce acceptance and trust 519 
fluctuations. The last group will be used to prospectively demonstrate the correlation between 520 
ATI, trust, and acceptance, thereby addressing Aim 3.2; retrospectively we will use the finalized 521 
method on all 80 participants to compute the auto -correlation between trust and acceptance 522 
and ATI and study the ability of ATI to track changes in time; Aim 3.3. Such an index, shown to 523 
follow the evolution of robustly assessed trust and acceptance (via standard methods) will enable 524 
future systems to characterize its interactions with its user, detecting early drop in adherence 525 
and disconnect with patient’s expectation (fault detection), and potentially associating them with 526 
specific functionalities (fault classification), leading to self -adaptations capable of optimizing 527 
system use and trust. 528 
 
 529 
This is a randomized crossover study in T1DM designed to demonstrate the efficacy of 530 
personalized feedback (PF) and decision support ( DSS) over sensor -augmented mode  (SAM) 531 
therapy  and to establish relationships between the level of glucose variability (GV) control 532 
achievable by the intervention and individual psycho -behavioral characteristics.  533 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 28 of 82  
 We plan to split the study into 4 cohorts of about 25 participants each (expected retention 20 534 
per cohort). Each cohort will continue for ~7 months and will have the structure presented in  535 
Figure 5 . Following recruitment, screening, and a run -in period of SAM, participants will be 536 
randomized into one of two groups: escalation vs . de-escalation of devices and function. Each 537 
treatment modality (SAM , PF, DSS) will continue for about 8 weeks, with the last 4 weeks used 538 
to assess GV from CGM data.  539 
 540 
Figure 5: Study design and timeline  541 
 
 542 
We anticipate recruiting a total of 100 adults aged 18 years and older . An e qual numbers of males 543 
and females will attempt to be recruited and all racial/ethnic groups will be eligible for 544 
participation. Based on our experience in previous studies of this magnitude, we expect that 80% 545 
of recruited subjects will complete the entire trial. Enrollment in the study will proceed with the 546 
goal of completing approximately 80 subjects. Up to 150 participants may sign the consent form. 547 
Eligibility criteria ensure that the subject will be able to fully deploy the technology in this study. 548 
Exclusions include any known medical condition that in the judgment of the investigator might 549 
interfere with the completion of the protocol.  550 
 
 551 
The study will be performed at the University of Virginia.   552 

CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 29 of 82  
 
 Study Devices  553 
 
 554 
The Diabetes Assistant (DiAs) system which is a medical platform that uses a smart -phone to 555 
connect to a continuous glucose sensor to insulin pump and run closed- loop control.  556 
 
 557 
For CSII participants, the study system will  include a modified  Tandem t:slim  X2 insulin pump 558 
(Tandem Diabetes Care, Inc., San Diego, CA), capable of communicating wirelessly with DiA s 559 
(t:AP).  560 
 
 561 
The study CGM will include Dexcom G6 ® transmitter and sensors (Dexcom, Inc., San Diego, CA)  562 
connected to the Diabetes Assistant (DiAs) .  563 
 
 564 
Blood ketone levels will be measured using Precision Xtra® meters and strips (Abbott 565 
Laboratories Inc., Alemeda, CA) in accordance with the manufacturer’s labeling. The blood 566 
glucose meter component of the Precision Xtra ® will not be used.  567 
 568 
 569 
Figure 6: Study Equipment   570 

CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 30 of 82  
 
 Study Screening  571 
 
 572 
Before consent has been obtained, participants will be asked inclusion/exclusion criteria 573 
questions during prescreening to determine study eligibility. Before completing any procedures 574 
or collecting any data that are not part of usual care, written informed consent will be obtained. 575 
Potential eligibility may be assessed as part of a routine -care examination.    576 
 A participant is considered enrolled when the informed consent form has been signed  by the 577 
participant and the study team . 578 
Consenting procedures and documentation is defined in section 16.3. 579 
Virtual study visits may take the place of all in-person study visits as deemed feasible by the study 580 
team.  581 
 
 582 
After informed consent has been signed, a potential participant will be evaluated for study 583 
eligibility through the elicitation of a medical history, performance of a physical examination 584 
by licensed study personnel, blood draw and urine pregnancy testing (if applicable) to screen for 585 
exclusionary medical conditions.  586 
The following procedures will be performed/data collected/eligibility criteria checked and 587 
documented:  588 
• Inclusion and exclusion criteria assessed  589 
• Demographics ( address, date of birth, gender, race , ethnicity) 590 
• Contact information  591 
• Diabetic history  592 
• Medical history  593 
• Medications  594 
• Physical examination  (may use a medical record within  the past 6 months)  595 
• Weight, height  (participant may self -report this information)  596 
• Vital signs including measurement of blood pressure and pulse  (may use a medical record 597 
within the past 6 months)  598 
• Urine or serum pregnancy test for all females of child -bearing potential  599 
• Chemistry panel, liver function tests, and thyroid stimulating hormone  600 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 31 of 82  
 • Diabetes Management Information: participant’s typical insulin dosing routine including 601 
average total daily insulin use (calculated over 1 week), basal rates, carbohydrate ratio(s), 602 
and correction factor(s)  603 
Screening procedures will last approximately 2 hours. Once all results of the screening 604 
evaluations are available, a decision will be made to determine the participant’s eligibility for the 605 
study or if one or more part of the screening will have to be repeated. If at the first screening or 606 
repeat screening an exclusionary condition is identified, the participant will be excluded from 607 
participation with follow up and referred to their primary care physician as needed. The study 608 
physician may elect to rescreen participants and collect additional laboratory values if their 609 
clinical situation changes.  610 
 
 611 
The participants must meet all of the following inclusion criteria in order to be eligible to 612 
participate in the study.  613 
• Age 18 years  and older 614 
• Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one 615 
year and using insulin for at least one year  616 
• HbA1c 6. 0-11.0%, inclusive  617 
• Demonstration of proper mental status and cognition for the study  618 
• If on a non -insulin hyperglycemic therapy, stability on that therapy for the prior 3 months 619 
and willingness not to alter the therapy for the study duration.  620 
• For females, not currently known to be pregnant  621 
• If female and sexually active, must agree to use a highly effective form of contraception 622 
to prevent pregnancy while a participant in the study.  A negative serum or urine 623 
pregnancy test will be required for all premenopausal women who are not surgically 624 
sterile.  Subjects who become pregnant will be discontinued from the study.  Also, 625 
subjects who during the study develop and express the intention to become pregnant 626 
within the timespan of the study will be discontinued.  627 
•  Subjects must have Internet access and a computer system that meets the requirements 628 
for uploading the study equipment and ability to participate in video conferencing.  629 
• Investigator has confidence that the subject can successfully operate all study devices and 630 
is capable of adhering to the protocol  631 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 32 of 82  
 
 
 632 
The participant must not have any exclusion criteria in order to be eligible to participate in the 633 
study.  634 
• NPH ( neutral protamine hagedorn) insulin   635 
• Use of any medication that at the discretion of the investigator is deemed to interfere 636 
with the trial.  637 
• Current treatment of a primary seizure disorder  638 
• Coronary artery disease or heart failure, unless written clearance is received from a 639 
cardiologist.  640 
• Hemophilia or any other bleeding disorder  641 
• A known medical condition, which in the opinion of the investigator or designee, would 642 
put the participant or study at risk such as the following examples:  643 
o Inpatient psychiatric treatment in the past 6 months  644 
o Presence of a known adrenal disorder  645 
o Abnormal liver function test results (Transaminase >3 times the upper limit of 646 
normal)  647 
o Abnormal renal function test results (calculated GFR <60 mL/min/1.73m2).  648 
o Active gastroparesis requiring medical therapy  649 
o Uncontrolled thyroid disease (TSH undetectable or >10 mlU/L).  650 
o Abuse of alcohol or recreational drugs  651 
o Infectious process not anticipated to be resolved prior to study procedures (e.g. 652 
meningitis, pneumonia, osteomyelitis, deep tissue infection).  653 
o Uncontrolled arterial hypertension (Resting diastolic blood pressure >100 mmHg 654 
and/or systolic blood pressure >180 mmHg).  655 
o Uncontrolled microvascular complications such as current active proliferative 656 
diabetic retinopathy defined as proliferative retinopathy requiring treatment (e.g. 657 
laser therapy or VEGF inhibitor injections) in the past 12 months.  658 
• A recent injury to body or limb, muscular disorder, use of any medication, any 659 
carcinogenic disease, or other significant medical disorder if that injury, medication or 660 
disease in the judgment of the investigator will affect the completion of the protocol.  661 
• Not familiar with smart phone technology  662 
• Current use of the following drugs and supplements:   663 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 33 of 82  
 o Oral steroids  664 
o Any other medication that the investigator believes is a contraindication to the 665 
subject’s participation  666 
• Participation  in another pharmaceutical or device trial at the time of enrollment or during 667 
the study . 668 
Screening procedures will last approximately 2 hours. Once all results of the screening 669 
evaluations are available, a decision will be made to determine the participant’s eligibility for the 670 
study or if one or more part s of the screening will have to be repeated. If at the first screening or 671 
repeat screening an exclusionary condition is identified, the participant will be excluded from 672 
participation with follow up and referred to their primary care physician as needed. The study 673 
physician may elect to rescreen participants and collect additional laboratory values if their 674 
clinical situation changes.  675 
 
 676 
If the subject is deemed eligible to participate in the study, t he subject will  elect to use either 677 
continuous subcutaneous insulin infusion (CSII) or MDI therapy for the duration of the study, no 678 
changes are allowed during the study. Furthermore, the participa nt will elect to use 679 
carbohydrates counting or not  for the computation of the meal bolus , this choice will apply to 680 
the entire study.   681 
Participants will then go through  a baseline psycho -behavioral assessment. The following 682 
questionnaires will be completed:  683 
• Diabetes Specific Personality Questionnaire  684 
• ABACUS  685 
• Diabetes Locus of Control  686 
• Confidence in Diabetes Self -Care Scale  687 
• Clarke's Hypoglycemia Awareness Scale Participant Inclusion Criteria  688 
• Demographic Data Survey (screening visit only)   689 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 34 of 82  
 
  Training Visit  690 
Participants may use  CSII or multiple daily insulin (MDI) injection therapy  for their diabetes 691 
management .  Participants  will be asked to maintain this treatment throughout the study.  In the 692 
event that MDI participants elects to change to CSII therapy  (see section 3.5), the run- in period 693 
will include a period of insulin stabilization for up to 6 weeks . The study physician may elect to 694 
extend this time frame if additional time would be beneficial to the participant.  695 
If participants intend on identifying carbohydrate counting (carbohydrate ratio, insulin sensitivity 696 
factor and glucose goal) at mealtime , they will be asked to continue to provide this information 697 
throughout  the study . 698 
 
 699 
4.1.1.  Study Continuous Glucose Monitor Training  700 
A Dexcom G6 CGM will be provided to all participants at the training session. The participants 701 
will be provided with CGM equipment and instructed to use the study CGM on a daily basis. If 702 
the participant has prior use of the CGM, re -training will be specific to the individual. The study 703 
team may elect to have less frequent CGM users watch the Dexcom online training videos 704 
(https://www.dexcom.com/training -videos) to assist in the training session.  Study staff training 705 
may include review of study CGM in real- time to make management decisions and how to review 706 
the data after an upload for retrospective review. Study staff will specifically identify how alarms 707 
are set using the app and the frequency that these alarms will repeat when  enabled.   708 
The participants personal CGM will be discontinued. The participants will be observed placing the 709 
sensor and will learn/review how to access the CGM trace. The participants will be asked to 710 
perform fingerstick blood glucose measurements (if needed) in accordance with the labeling of 711 
the study CGM device.  712 
An electronic copy of the CGM user’s guide will be provided for the participants to take home. 713 
The study team will be sure that the participants will leave the clinic knowing how to proper ly 714 
use the CGM.  715 
Upon request, t he study team will provide a Dexcom receiver to allow participants to share their 716 
CGM data with their personal care providers.  717 
4.1.2.  Study Pump (Tandem t:AP) Training  (CSII participants)  718 
Eligible participants will be fully instructed on the study insulin pump. A qualified staff member 719 
will conduct the training and discuss particular differences from the home pump in important 720 
aspects such as calculation of insulin on board and correction boluses.  721 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 35 of 82  
 Additional training topics are not limited to but may include: infusion site initiation, 722 
cartridge/priming procedures, setting up the pump, charging the pump, navigation through 723 
menus, bolus procedures including stopping a bolus, etc.  724 
The study pump will be programmed with the subject’s usual basal rates and pump parameters.  725 
The study team will assist the subject in study pump infusion site initiation and will assist the 726 
subject on starting the study pump.  727 
The subject’s personal pump will be removed.  728 
The subject will be supervised with the study pump during at least one meal or snack bolus to 729 
ensure subject understanding of the pump features.  730 
The subject will be encouraged to review the literature provided with the pump and infusion sets 731 
after the training is completed.  732 
4.1.3.  DiAs Training  733 
Prior to initial use, the DiAs will be initialized by a study team member with the participant’s 734 
individual insulin dosing parameters, including carbohydrate ratio, insulin sensitivity factor and 735 
basal insulin dose s. If applicable, t he study team will confirm the carbohydrate counting 736 
parameters entered in the system with the study physician.  737 
Qualified study team members will train the subject in performing specific tasks including the 738 
following:  739 
• How to view the CGM information including the most recent CGM value, trend arrow, and 740 
CGM graph.  Low and high threshold alerts will be set. The patient may choose the 741 
threshold alert values, but the low alert may not be set to <70 mg/dL and the high alert 742 
may not exceed 300 mg/dL.  743 
• How to connect the CGM transmitter to DiAs as well as troubleshooting techniques for 744 
reconnecting. If the CGM values are not available, the subject will be asked to perform 745 
fingerstick BG measurements for insulin dosing and treatment management.  746 
• How to start and stop a sensor session with the DiAs APP . 747 
• [for CSII participants] How to connect the pump to DiAs and troubleshooting steps for 748 
reconnection.  749 
• [For MDI participants] How to retroactively inform the system of past insulin doses  750 
• How to activate the “meal” screen of the DiAs system any time meal insulin or additional 751 
correction insulin is desired . And how to use the selected bolus calculator (different if 752 
counting carbohydrates or not , see section 3.5).  753 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 36 of 82  
 • How to inform the system of hypoglycemia treatment via a “hypoglycemia treatment” 754 
button on the DiAs user interface after glucose is consumed that is not accompanied by 755 
an insulin bolus . 756 
• What to do when exercising while using the system and how to use a temporary basal 757 
rate. 758 
• How to accept DiAs  mode changes sent remotely by the study team.  759 
DiAs instructions will be provided in the study training manual.  760 
4.1.4.  Ketone Meter Training  761 
Subjects will be provided with a study blood ketone meter, test strips, and standard control 762 
solution to perform QC testing per manufacturer guidelines.  QC will be completed prior to subject 763 
receiving the study ketone meter. Only meters that read within the target range at two 764 
concentrations per manufacturer labeling will be used in the study.  The subject will be instructed 765 
to contact study staff for a replacement of the meter, test strips, and control solution if a meter 766 
fails QC testing at home.   767 
Subjects will be instructed to perform blood ketone testing per the Glycemic Treatment  768 
Guidelines located in the study training manual . 769 
 
 770 
After randomization,  all participants will be trained on how to access and complete EMAs from 771 
their study phone, how to postpone alerts, and enter a voluntary diary. Participants will be 772 
informed when the EMAs are scheduled during each phase of the trial.   773 
 
 774 
A home glucagon emergency kit will be required. Participants who currently do not have one will 775 
be given a prescription for the glucagon emergency kit.   776 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 37 of 82  
 
 Study Procedures 777 
 
 778 
5.1.1.  Study Support  779 
Participants  will also receive study staff contact information to ask any questions they may have 780 
during the study. Additionally, participants will be provided with study contact information for 781 
technical support with DiAs  System , the study insulin pump and the study CGM. The partic ipant  782 
will be asked to call the study team  at any time during the study for any health -related issues  783 
(adverse events),  including hypoglycemia <54 mg/dL, frequent highs >300 mg/dL, or ketones ≥3.0 784 
mmol/L. The participant may use the study pump and study CGM during periods of DiAs 785 
disconnections or technical difficulties.  786 
5.1.2.  Web C onferencing  787 
Study visits may be completed using HIPAA compliant web conference tool. The study team will 788 
provide the participant with the meeting information  in advance of the appointment .  789 
 
 790 
5.2.1.  CGM use  791 
Once all training activities are completed, the participant will be given adequate supplies to 792 
complete the Run -in home use of the DiAs system in SAM .  793 
Participants will complete a minimum of 14 days  (if CGM use within the preceding 3 months) or 794 
4 weeks (if no CGM use within the preceding 3 months) of home use of the DiAs system in SAM . 795 
The study physician may request an additional run-in period of 2 weeks.  796 
The participant will be informed that in order to be eligible for the study, the DiAs system in SAM  797 
must be used on a minimum of 11 out of 14 days for CGM users or 22 out of 28 days CGM 798 
nonusers.  799 
An appointment for Visit 3 will be scheduled.  800 
5.2.2.  Questionnaires  801 
Participants will be sent the following questionnaires on the final week of the Run- in Period and 802 
will be asked to complete them within 1 week:                                                                               803 
• T1-Diabetes Distress Scale    804 
• Hypoglycemia Fear Survey  805 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 38 of 82  
 • Hyperglycemia Avoidance Scale  806 
 
 807 
The participant may complete this v isit via web conferencing and/or at the study site.  808 
5.3.1.  Eligibility Assessment  809 
The CGM and insulin  data will be reviewed to assess whether the subject has used the DiAs 810 
system in SAM  on at least 11 out of 14 days for CGM users or 22 out of 28 days for non-CGM 811 
users. Subjects who are unable to meet the CGM and DiAs  compliance requirement will be 812 
withdrawn from the study, unless the investigator believes that there were extenuating 813 
circumstances that prevented successful completion. In such cases, the investigator may ask the 814 
participant to repeat this eligibility assessment.  815 
5.3.2.  Adverse Event  Assessment  816 
The participant will be asked about any of adverse events, adverse device effects, and device 817 
issues since the last visit. The participant will also be asked if there were any low BGs <54 mg/dL, 818 
high BGs >300 mg/dL, or ketones ≥3.0 mmol/L since the last visit.  Participants will be encouraged 819 
to contact the study team between visits as needed (i.e. report adverse events in real -time).   820 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 39 of 82  
 
 Study Procedures - Escalation 821 
6.1.1.  Randomization  to Escalation  822 
Eligible subjects will be randomized to therapy escalation ( SAM →PF→DSS).  823 
A baseline Hemoglobin A1C will be collected. The participant will receive a mode change for 824 
Phase 1 according to the randomization scheme.  825 
 
 826 
Participants randomized to escalation will have any questions answered about continuing use of 827 
the DiAs system in SAM . 828 
6.2.1.  SAM  EMA Surveys  829 
Over the course of  2-3 days  every two weeks of Phase 2, the participant will be asked to complete 830 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 831 
participant during each Phase.  832 
6.2.2.  Phase 1 Initiation Questionnaires  833 
Participants randomized to escalation will complete the following questionnaires:  834 
• Pittsburgh Sleep Quality Index  835 
Once all training activities are completed, the participant will be given adequate supplies and 836 
study devices to last until the subsequent clinic visit. An appointment for Visit 4 will be scheduled  837 
 
 838 
The participant will complete a minimum of 8 weeks of DiAs use in Phase 1 Mode at home. During 839 
the course of Phase 1, participants will complete EMA surveys and post- phase questionnaires.  840 
6.3.1.  Phase 1 EMA Surveys  841 
Over the course of  2-3 days  every two weeks of Phase 1, the participant will be asked to complete 842 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 843 
participant during each Phase.  844 
6.3.2.  Post -Phase 1 Questionnaires Week 7  845 
Participants randomized to escalation will be sent the following questionnaires on week 7 (day 846 
42 of Phase 1) and will be asked to complete them within 1 week:  847 
• Pittsburgh Sleep Quality Index   848 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 40 of 82  
 • Hyperglycemia Avoidance Scale  849 
6.3.3.  Post -Phase 1 Questionnaires Week 8  850 
Participants randomized to escalation will sent the following questionnaires on week 8 (day 49 851 
of Phase 1) and will be asked to complete them within 1 week:  852 
• Confidence in Diabetes Self -Care Scale  853 
• T1-Diabetes Distress Scale  854 
• Hypoglycemia Fear Survey  855 
 
 856 
All participants in each randomization scheme use PF in Phase 2. Phase 2 initiation may be 857 
conducted either via web conference or an office visit. The participant will remotely receive a 858 
mode change for Phase 2. Study staff will review the features of the Personalized Feedback (PF) 859 
mode and answer any questions. Participant will have a blood/urine pregnancy test that must be 860 
negative in order to continue to participate in this study.  861 
6.4.1.  Training on Phase 2 DiAs Mode 862 
The participant will be trained on the following features of the Personalized Feedback System:  863 
• Tracking of estimated HbA1c:  When properly calibrated, eA1c  is within 0.3% of 864 
reference HbA1c on average, and within 1% of HbA1c >95% of the time.  865 
• Hypoglycemia Risk Indicator:  Provides an indication of the current risk for 866 
hypoglycemia.  867 
• Insulin Sensitivity Profile & Indicator:  Tracks changes in insulin sensitivity (SI) and 868 
creates daily and monthly SI profiles.  869 
• Insulin on Board:  Tracks active insulin to avoid insulin stacking using a common 4 -6 hour 870 
action curve . 871 
• Personalized weekly feedback.  Provides advice to the user on what went well in terms 872 
of glycemic control and system use in the past week and what may be a good thing to 873 
focus on for the following week.  874 
6.4.2.  Phase 2 Initiation Questionnaires  875 
Participants randomized to escalation will complete the following questionnaires:  876 
• Technology Expectations (burdens subscale only)  877 
• INSPIRE (revised for DSS)  878 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 41 of 82  
 6.4.3.  Adverse Event  Assessment  879 
The participant will be asked about any of adverse events, adverse device effects, and device 880 
issues since the last visit. The participant will also be asked if there were any low BGs <54 mg/dL, 881 
high BGs >300 mg/dL, or ketones ≥3.0 mmol/L since the last visit.  882 
Once all training activities are completed, the participant will be given adequate supplies and 883 
study devices to last until the subsequent clinic visit. An appointment for Visit  5 will be scheduled. 884 
Participants will be encouraged to contact the study team between visits as needed (i.e. report 885 
adverse events in real -time).  886 
 
 887 
The participant will complete a minimum of 8 weeks of DiAs use in Phase 2 Mode at home.  888 
During the course of Phase 2, participants will complete EMA surveys and post -phase 889 
questionnaires.  890 
6.5.1.  Phase 2 EMA Surveys  891 
Over the course of  2-3 days  every two weeks of Phase 2, the participant will be asked to complete 892 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 893 
participant during each Phase.  894 
6.5.2.  Post -Phase 2 Questionnaires Week 7  895 
All participants will be sent the following questionnaires on week 7 (day 42 of Phase 2) and will 896 
be asked to complete them within 1 week:  897 
• Technology Acceptance (burdens subscale only)  898 
• Pittsburgh Sleep Quality Index  899 
• T1-Diabetes Distress Scale  900 
6.5.3.  Post -Phase 2 Questionnaires Week 8  901 
All participants will be sent the following questionnaires on week 8 (day 49 of Phase 2) and will 902 
be asked to complete them within 1 week:  903 
• Hypoglycemia Fear Survey  904 
• Hyperglycemia Avoidance Scale  905 
• Confidence in Diabetes Self -Care Scale  906 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 42 of 82  
 
 
 907 
The participant will begin Phase 3 according to the randomization scheme either via web 908 
conference or an office visit. The participant will remotely receive a mode change for Phase 3. 909 
Study staff will review the features of the Phase 3 system and answer any questions. Participant 910 
will have a blood/urine pregnancy test that must be negative in order to continue to participate 911 
in this study.  912 
6.6.1.  Training on Phase 3 DiAs Mode  913 
Participants randomized to escalation will be trained to use DiAs in DSS mode, including the 914 
following features:  915 
• Exercise Advice:  An advisory module that ensures safety of mild to moderate exercise 916 
by predicting whether an exercise bout is likely to result in hypoglycemia and providing 917 
a graded carbohydrate supplementation strategy and possible reduction in insulin 918 
advice.  919 
• Bedtime Advice:  Gauges overnight hypoglycemia risk and provides bedtime 920 
carbohydrate advice.  921 
• Smart Bolus Calculator:  An advanced bolus calculator capable of accounting for several 922 
factors such as exercise (activity on board), metabolic characteristics (correction based 923 
on 45 min predicted glucose to account for insulin delays) and SI fluctuations (insulin 924 
sensitivity tracker).  925 
• Treatment Parameter Optimization:  An optimization routine that analyzes the previous 926 
30 days of CGM, insulin, and meal data to provide updated insulin treatment 927 
parameters (CR, CF, and basal rate) to minimize glycemic risk.  928 
6.6.2.  Phase 3 Initiation Questionnaires  929 
Participants randomized to escalation will complete the following questionnaires:  930 
• Technology Expectations (burdens subscale only)  931 
• INSPIRE (revised for DSS)  932 
• Diabetes Locus of Control  933 
6.6.3.  Adverse Event  Assessment  934 
 The participant will be asked about any of adverse events, adverse device effects, and device 935 
issues since the last visit. The participant will also be asked if there were any low BGs <54 mg/dL, 936 
high BGs >300 mg/dL, or ketones ≥3.0 mmol/L since the last visit.  Participants will be encouraged 937 
to contact the study team between visits as needed (i.e. report adverse events in real -time).  938 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 43 of 82  
 
 
 939 
The participant will complete a minimum of 8 weeks of Phase 3 at home. During the course of 940 
Phase 3, participants will complete EMA surveys and post -phase questionnaires.  941 
6.7.1.  Phase 3 EMA Surveys  942 
Over the course of  2-3 days  every two weeks of Phase 3, the participant will be asked to complete 943 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 944 
participant during each Phase.  945 
6.7.2.  Post -Phase 3 Questionnaires Week 7  946 
Participants randomized to escalation will be sent the following questionnaires on week 7 (day 947 
42 of Phase 1) and will be asked to complete them within 1 week:  948 
• Technology Acceptance (burdens subscale only)  949 
• Pittsburgh Sleep Quality Index.  950 
• T1-Diabetes Distress Scale  951 
6.7.3.  Post -Phase 3 Questionnaires Week 8  952 
Participants randomized to escalation will sent the following questionnaires on week 8 (day 49 953 
of Phase 3) and will be asked to complete them within 1 week:  954 
• Hypoglycemia Fear Survey  955 
• Hyperglycemia Avoidance Scale  956 
• Confidence in Diabetes Self -Care Scale  957 
 
 958 
Participants will participate in a Study Exit visit either via web conference or an office visit.  959 
Participants will return to their  standard diabetes care using their personal equipment .  The study 960 
team will be available to answer questions about insulin parameters.   961 
The participant will be asked to return all investigational study devices (e.g. study insulin pump, 962 
study, CGM, study phone, other associated supplies) either via mail or at an office visit. 963 
Participants may keep the study glucometer and ketone meter.  964 
6.8.1.  Study Exit Questionnaires  965 
Participants randomized to escalation will complete the following questionnaires:  966 
• ABACUS  967 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 44 of 82  
 • INSPIRE (revised for DSS)  968 
• Diabetes Locus of Control  969 
6.8.2.  Adverse Event  Assessment  970 
The participant will be asked about any of adverse events, adverse device effects, and device 971 
issues since the last visit. The participant will also be asked if there were any low BGs <54 mg/dL, 972 
high BGs >300 mg/dL, or ketones ≥3.0 mmol/L since the last visit.  973 
 
 974 
Approximately 48 hours after the home use of the equipment, the study team will contact the 975 
participant  via phone/email/text to assess:  976 
• Adverse events, adverse device effects, and device issues  977 
• Blood glucose values <60 mg/dL and >300 mg/dL   978 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 45 of 82  
 
 Study Procedures – De-Escalation 979 
 
 980 
Eligible subjects will be randomized to therapy de -escalation (DSS→PF→ SAM ).  981 
A baseline Hemoglobin  A1C will be collected.   982 
The participant will receive a mode change for Phase 1 according to the randomization scheme.  983 
 
 984 
Participants randomized to de -escalation will be trained to use DiAs in DSS mode, including the 985 
following features:  986 
• Exercise Advice:  An advisory module that ensures safety of mild to moderate exercise by 987 
predicting whether an exercise bout is likely to result in hypoglycemia and providing a 988 
graded carbohydrate supplementation strategy and possible reduction in insulin advice.  989 
• Bedtime Advice:  Gauges overnight hypoglycemia risk and provides bedtime carbohydrate 990 
advice.  991 
• Smart Bolus Calculator:  An advanced bolus calculator capable of accounting for several 992 
factors such as exercise (activity on board), metabolic characteristics (correction based 993 
on 45 min predicted glucose to account for insulin delays) and SI fluctuations (insulin 994 
sensitivity tracker).  995 
• Treatment Parameter Optimization:  An optimization routine that analyzes the previous 996 
30 days of CGM, insulin, and meal data to provide updated insulin treatment parameters 997 
(CR, CF, and basal rate) to minimize glycemic risk.  998 
7.2.1.  Phase 1 EMA  Surveys  999 
Over the course of  2-3 days  every two weeks of Phase 2, the participant will be asked to complete 1000 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 1001 
participant during each Phase.  1002 
7.2.2.  Phase 1 Initiation Questionnaires  1003 
Participants randomized to de -escalation will complete the following questionnaires: 1004 
• Pittsburgh Sleep Quality Index  1005 
• Technology Expectations (burdens subscale only)  1006 
• INSPIRE (revised for DSS)  1007 
Once all training activities are completed, the participant will be given adequate supplies and 1008 
study devices to last until the subsequent clinic visit. An appointment for Visit 4 will be scheduled.  1009 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 46 of 82  
 
 
 1010 
The participant will complete a minimum of 8 weeks of DiAs use in Phase 1 Mode at home. During 1011 
the course of Phase 1, participants will complete EMA surveys and post- phase questionnaires.  1012 
7.3.1.  Phase 1 EMA Surveys  1013 
Over the course of  2-3 days  every two weeks of Phase 1, the participant will be asked to complete 1014 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 1015 
participant during each Phase.  1016 
7.3.2.  Post -Phase 1 Questionnaires Week 7  1017 
Participants randomized to de -escalation will be sent the following questionnaires on week 7 1018 
(day 42 of Phase 1) and will be asked to complete them within 1 week:  1019 
• Technology Acceptance (burdens subscale only)  1020 
• Pittsburgh Sleep Quality Index  1021 
• T1-Diabetes Distress Scale  1022 
7.3.3.  Post -Phase 1 Questionnaires Week 8  1023 
Participants randomized to de -escalation will be sent the following questionnaires on week 8 1024 
(day 49 of Phase 1) and will be asked to complete them within 1 week:  1025 
• Hypoglycemia Fear Survey  1026 
• Hyperglycemia Avoidance Scale  1027 
• Confidence in Diabetes Self -Care Scale  1028 
 
 1029 
All participants in each randomization scheme use PF in Phase 2. Phase 2 initiation may be 1030 
conducted either via web conference or an office visit. The participant will remotely receive a 1031 
mode change for Phase 2. Study staff will review the features of the Personalized Feedback (PF) 1032 
mode and answer any questions.  1033 
7.4.1.  Training on Phase 2 DiAs Mode 1034 
The participant will be trained on the following features of the Personalized Feedback System:  1035 
• Tracking of estimated HbA1c:  When properly calibrated, eA1c  is within 0.3% of reference 1036 
HbA1c on average, and within 1% of HbA1c >95% of the time.  1037 
• Hypoglycemia Risk Indicator:  Provides an indication of the current risk for hypoglycemia.  1038 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 47 of 82  
 • Insulin Sensitivity Profile & Indicator:  Tracks changes in insulin sensitivity (SI) and creates 1039 
daily and monthly SI profiles.  1040 
• Insulin on Board:  Tracks active insulin to avoid insulin stacking using a common 4 -6 hour 1041 
action curve . 1042 
• Personalized weekly feedback.  Provides advice to the user on what went well in terms of 1043 
glycemic control and system use in the past week and what may be a good thing to focus 1044 
on for the following week.  1045 
7.4.2.  Phase 2 Initiation Questionnaires  1046 
Participants randomized to de -escalation will complete the following questionnaires: 1047 
• Technology Expectations (burdens subscale only)  1048 
• INSPIRE (revised for DSS)  1049 
• Diabetes Locus of Control  1050 
7.4.3.  AE Assessment  1051 
The participant will be asked about any of adverse events, adverse device effects, and device 1052 
issues since the last visit. The participant will also be asked if there were any low BGs <54 mg/dL, 1053 
high BGs >300 mg/dL, or ketones ≥3.0 mmol/L since the last visit.  1054 
Once all training activities are completed, the participant will be given adequate supplies and 1055 
study devices to last until the subsequent clinic visit. An appointment for Visit 5 will be scheduled.  1056 
 
 1057 
The participant will complete a minimum of 8 weeks of DiAs use in Phase 2 Mode at home.  1058 
During the course of Phase 2, participants will complete EMA surveys and post -phase 1059 
questionnaires.  1060 
7.5.1.  Phase 2 EMA Surveys  1061 
Over the course of  2-3 days  every two weeks of Phase 2, the participant will be asked to complete 1062 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 1063 
participant during each Phase.  1064 
7.5.2.  Post -Phase 2 Questionnaires Week 7  1065 
All participants will be sent the following questionnaires on week 7 (day 42 of Phase 2) and will 1066 
be asked to complete them within 1 week:  1067 
• Technology Acceptance (burdens subscale only)  1068 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 48 of 82  
 • Pittsburgh Sleep Quality Index  1069 
• T1-Diabetes Distress Scale  1070 
7.5.3.  Post -Phase 2 Questionnaires Week 8  1071 
All participants will be sent the following questionnaires on week 8 (day 49 of Phase 2) and will 1072 
be asked to complete them within 1 week:  1073 
• Hypoglycemia Fear Survey  1074 
• Hyperglycemia Avoidance Scale  1075 
• Confidence in Diabetes Self -Care Scale  1076 
 
 1077 
The participant will begin Phase 3 according to the randomization scheme either via web 1078 
conference or an office visit. The participant will remotely receive a mode change for Phase 3. 1079 
Study staff will review the features of the Phase 3 system and answer any questions.  1080 
7.6.1.  Training on Phase 3 DiAs Mode  1081 
Participants randomized to de -escalation will have any questions answered about resuming use 1082 
of the DiAs system in  SAM . 1083 
7.6.2.  Phase 3 Initiation Questionnaires  1084 
Participants randomized to de -escalation will complete the following questionnaires:  1085 
• INSPIRE (revised for DSS)  1086 
• Diabetes Locus of Control  1087 
7.6.3.  Adverse Event  Assessment  1088 
The participant will be asked about any of adverse events, adverse device effects, and device 1089 
issues since the last visit. The participant will also be asked if there were any low BGs <54 mg/dL, 1090 
high BGs >300 mg/dL, or ketones ≥3.0 mmol/L since the last visit.  1091 
Once all training activities are completed, the participant will be given adequate supplies and 1092 
study devices to last until the subsequent clinic visit. An appointment for Visit 6 will be scheduled. 1093 
Participants will be encouraged to contact the study team between visits as needed (i.e. report 1094 
adverse events in real -time).  1095 
 
 1096 
The participant will complete a minimum of 8 weeks of Phase 3 at home. During the course of 1097 
Phase 3, participants will complete EMA surveys and post -phase questionnaires.  1098 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 49 of 82  
 7.7.1.  Phase 3 EMA Surveys  1099 
Over the course of  2-3 days  every two weeks of Phase 3, the participant will be asked to complete 1100 
a “Daily Diary” with 3 -5 entries  of 3-4 questions each day, for a minimum total of 48  entries  per 1101 
participant during each Phase.  1102 
7.7.2.  Post -Phase 3 Questionnaires Week 7  1103 
Participants randomized to de -escalation will be sent the following questionnaires on week 7 1104 
(day 42 of Phase 1) and will be asked to complete them within 1 week:  1105 
• Pittsburgh Sleep Quality Index  1106 
• T1-Diabetes Distress Scale  1107 
7.7.3.  Post -Phase 3 Questionnaires Week 8  1108 
Participants  randomized to de -escalation will be sent the following questionnaires on week 8 1109 
(day 49 of Phase 1) and will be asked to complete them within 1 week:  1110 
• Hypoglycemia Fear Survey  1111 
• Hyperglycemia Avoidance Scale (HAS)  1112 
• Confidence in Diabetes Self -Care Scale  1113 
 
 1114 
Participants will participate in a Study Exit visit either via web conference or an office visit.  1115 
Participants will return to their  standard diabetes care using their personal equipment .  The study 1116 
team will be available to answer questions about insulin parameters.   1117 
The participant will be asked to return all investigational study devices (e.g. study insulin pump, 1118 
study, CGM, study phone, other associated supplies) either via mail or at an office visit. 1119 
Participants may keep the study glucometer and ketone meter.  1120 
7.8.1.  Study Exit Questionnaires  1121 
Participants randomized to de -escalation will complete the following questionnaires:  1122 
• ABACUS  1123 
7.8.2.  Adverse Event  Assessment  1124 
The participant will be asked about any of adverse events, adverse device effects, and device 1125 
issues since the last visit. The participant will also be asked if there were any low BGs <54 mg/dL, 1126 
high BGs >300 mg/dL, or ketones ≥3.0 mmol/L since the last visit.   1127 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 50 of 82  
 
 
 1128 
Approximately 48 hours after the home use of the equipment, the study team will contact the 1129 
participant via phone/email/text to assess:  1130 
• Adverse events, adverse device effects, and device issues  1131 
• Blood glucose values <60 mg/dL and >300 mg/dL   1132 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 51 of 82  
 
 Testing Procedures  1133 
 
 1134 
8.1.1.  HbA1c  1135 
• A blood sample will be obtained at screening to obtain a baseline hemoglobin A1c level.  1136 
• HbA1c level may be measured by study team using the DCA2000, a comparable point of 1137 
care device , at time of screening   1138 
• Labs may be obtained at a local laboratory (e.g. LabCorp) convenient to the participant.  1139 
• Blood test may be obtained within 14 days  prior to enrollment may be used for eligibility 1140 
purposes.   1141 
• Sample collected at randomization and end of study will be used for statistical purposes.  1142 
8.1.2.  Comprehensive Metabolic Panel  1143 
• A blood sample will be obtained at screening to assess kidney and liver functioning.  1144 
• Labs may be obtained at a local laboratory (e.g. LabCorp) convenient to the participant.  1145 
• Blood test may be obtained within 14 days prior to enrollment may be used for eligibility 1146 
purposes.  1147 
8.1.3.  Thyroid Stimulating Hormone 1148 
• A blood sample will be obtained at screening to assess thyroid function.  1149 
• Labs may be obtained at a local laboratory (e.g. LabCorp) convenient to the participant.  1150 
• Blood test may be obtained within 14 days  prior to enrollment may be used for eligibility 1151 
purposes.   1152 
8.1.4.  Pregnancy Test  1153 
A blood/ urine pregnancy test will be required for women of childbearing  potential at the 1154 
screening visit , and between each phase .  Test s must be negative to participate in the study.   1155 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 52 of 82  
 
 Questionnaires & Ecological Momentary Analysis  1156 
 
 1157 
The Diabetes Specific Personality Questionnaire is based on the original Six Factor Personality 1158 
Questionnaire  [81], a well -validated measure that was adapted for the diabetes -specific version 1159 
of the questionnaire. The Six Factor Personality Questionnaire  is a measure of six personality 1160 
dimensions each consisting of three facet scales, measured by 108 Likert items. The Six Factor 1161 
Personality Questionnaire  facet scales  are organized in terms of six factor  scales.  The Diabetes 1162 
Specific Personality Questionnaire assesses  three personality factors – conscientiousness, 1163 
obsessive -compulsiveness, and openness. In this study, the Diabetes Specific Personality 1164 
Questionnaire  is used to explore whether personality type is associated with willingness and/or 1165 
ability to effectively engage with the D SS. Administration time is approximately 15  minutes . 1166 
 
 1167 
This is a structured interview used to provide a very brief assessment of carbohydrate counting 1168 
and diabetes self -management skills important to effective engagement consisting of a series of 1169 
25 questions assessing health literacy and health numeracy in people with T1DM  [84].. The 1170 
interviewer evaluates the subject answer to each question on a scale ranging from 1 (No 1171 
competency) to 3 (Full competency); the sum yields to a total score. The higher the score, the 1172 
higher the levels of health literacy and numeracy of the subject. Administration time is 1173 
approximately 10 -20 minutes . 1174 
 
 1175 
This questionnaire [85] was developed for use on adults (18 -80 y.o.) The scale consists of 18 items 1176 
measuring the individual’s personal beliefs about their control over their diabetes management 1177 
and outcome: 6 items measuring internal locus of control, 6 items measuring powerful others 1178 
locus of control, and 6 items measuring chance locus of control. A 6 -point Likert -type scale is used 1179 
in which 0 indicates ‘strongly disagree with the statement’ and 5 indicates ‘strongly agree with 1180 
the statement.’ Administration time is approximately 5 minutes . 1181 
 
 1182 
This is a short 20 -item self -report questionnaire assessing self -efficacy, the perceived ability to 1183 
perform diabetes self -care tasks, in patients with T1DM  [87]. Items are constructed to cover all 1184 
domains of self -care as well as social skills. Each item is preceded by, “I believe I can…” with the 1185 
strength of this belief rated on a 5 -point Likert scale ranging from 1 (“No, I am sure I cannot”) to 1186 
5 (“Yes, I am sure I can”). Administration time is approximately 10 minutes . 1187 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 53 of 82  
 
 
 1188 
The scale comprises eight questions characterizing the participant's level of hypoglycemia 1189 
awareness, as well as risk for exposure to episodes of moderate and severe hypoglycemia  [88]. 1190 
It also examines the glycemic threshold for symptomatic responses to hypoglycemia. A score of 1191 
four or more on a scale of 0 to 7 implies impaired awareness of hypoglycemia.  Administration 1192 
time is approximately 5 minutes . 1193 
 
 1194 
This is a measure that reflects diabetes -specific quality of life and emotional well-being  [90]. The 1195 
Diabetes Distress Scale is a measure of diabetes -related distress over a number of domains (e.g. 1196 
diabetes management regimen, interpersonal distress) and consists of a scale of 17 items. These 1197 
include items from each of four domains central to diabetes -related emotional distress. Patients 1198 
rate the degree to which each item is currently problematic for them on a 6 -point Likert scale, 1199 
from 1 (no problem) to 6 (serious problem). Administration time is approximately 5 minutes . 1200 
 
 1201 
This questionnaire will be used to determine if the PF and DSS is associated with reduced fear of 1202 
hypoglycemia . The Hypoglycemia Fear Survey -II [91] was developed to measure behaviors and 1203 
worries related to fear of hypoglycemia in adults with T1DM . It is composed of 2 subscales, the 1204 
Behavior and Worry. B ehavior  items describe behaviors in which patients may engage to avoid 1205 
hypoglycemic episodes and/or their negative consequences (e.g., keeping blood glucose levels 1206 
higher, making sure other people are around, and limiting exercise or physical activity). W orry 1207 
items describe specific concerns that patients may have about their hypoglycemic episodes (e.g., 1208 
being alone, episodes occurring during sleep, or having an accident). Items are rated on a 5 -point 1209 
Likert scale (0=never, 4=always), with higher scores indicating higher fear of hypoglycemia. 1210 
Administration time is approximately 10 minutes . 1211 
 
 1212 
This measure is used to assess the extent of potentially problematic avoidant attitudes and 1213 
behaviors in people with T1DM [91]. The H ypoglycemia Avoidance Scale reliably quantifies 1214 
affective and behavioral aspects of hyperglycemia avoidance and is used to assess the extent of 1215 
potentially problematic avoidant attitudes and behaviors regarding hyperglycemia in people with 1216 
T1DM .  It has 24 items plus two additional optional items asking about the highest level of daily 1217 
blood glucose or HbA1c measures the individual would feel comfortable having. Administration 1218 
time is approximately 10 minutes . 1219 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 54 of 82  
 
 
 1220 
This questionnaire will be used to assess whether the PF and DSS improve sleep quality and 1221 
quantity. The Pittsburgh Sleep Quality Index [ 93] is a self -report questionnaire that assesses sleep 1222 
quality over a 1 -month time interval. The measure consists of 19 individual items, creating 7 1223 
components that produce one global score: the higher the global score, the poorer the sleep 1224 
quality.  Administration time is approximately 5 -10 minutes . 1225 
 
 1226 
The Technology Acceptance Surveys [94-95] were developed for an artificial pancreas camp study 1227 
in adolescents. The 38 items in the questionnaire were based on interviews conducted with 1228 
individuals who had participated in previous artificial pancreas trials about their experience 1229 
regarding the device. It was subsequently adapted to assess these same measures for the PF and 1230 
DSS. It assesses both positive and negative experiences with PF and DSS, including blood glucose 1231 
management, device burden, and overall satisfaction. Items a re rated on a 5 -point scale. In this 1232 
study only the burden subscale will be used.  The Technology Expectations Survey has the same 1233 
items included on the Technology Acceptance Survey but asks whether the individual expects to 1234 
experience the various benefits and burdens from use of a device. Administration time is 1235 
approximately 10 minutes . 1236 
 
 1237 
This questionnaire will be used to assess patient preferences to support effective onboarding and 1238 
successful continued use of the PF and DSS. The INSPIRE survey was developed to assess various 1239 
aspects of a user’s experience regarding automated insulin delivery for both patients and family 1240 
members. The surveys include various topics important to patients with T1DM  and their family 1241 
members based upon >200 hours of  qualitative interviews and focus groups. It was adapted by 1242 
its developer for use with the PF  and DSS . The survey includes 22 items. Response options include 1243 
a 5-point Likert scale from strongly agree to strongly disagree, along with an N/A option.  1244 
Administration time is approximately 5 minutes.  1245 
 
 1246 
In addition to the behavioral data automatically recorded (e.g. insulin dosing, interactions with 1247 
system), an EMA procedure will be used to track the users’ daily experiences of trust in the 1248 
system, emotional well -being, treatment satisfaction, and diabetes -related concerns and burden.  1249 
Using a brief daily survey, we will capture the dynamic changes in participant experience 1250 
throughout the day and the associations between users’ subjective experience and their 1251 
reactions to/interactions with the PF and DSS devices. This will be the first use of EMA with 1252 
decision support systems.  1253 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 55 of 82  
 During each treatment condition,  over the course of  2-3 days  every two weeks,  the participant 1254 
will be asked to complete a “Daily Diary” with 3 -5 entries  of 3 -4 questions each day, for a 1255 
minimum total of 48  entries  per participant during each Phase.  1256 
The DiAs phone will display a text message containing a link to the survey. Surveys will be 1257 
triggered at fixed times, including a morning survey ~1h after waking up and an end- of-the-day 1258 
survey around 8 -9 PM . Participants will be able to delay (up to 30 min) or skip (up to 2 per day 1259 
excluding at wake up) surveys for their convenience.   1260 
Participants will respond to questions on a 5 -point Likert scale (0=Not at All, 4=Extreme ly). The 1261 
first Diary for each day will contain two additional items for rating sleep quantity/quality.  1262 
The Daily Diary questions are shown below and are intended to assess agreement, trust, 1263 
treatment satisfaction, diabetes burden, self -efficacy, mood valence, energy level, and  physical 1264 
well-being.  1265 
• Quality of Life Parameters  1266 
 At this moment, to what extent do you feel... 1267 
 Burdened by your diabetes treatment?  1268 
 Worried about your blood sugar levels?  1269 
 In a positive or good mood?  1270 
 Physically  well?   1271 
• Sleep Items  (only presented in the first Diary for each day)  1272 
 Was your sleep last night…  1273 
 Long enough?  1274 
 Restful enough?  1275 
• Technology acceptance (only presented in the last Diary for each day)  1276 
 Today to what extent have you... 1277 
 Found (name of program) easy  to use?  1278 
 Found (name of program) useful?  1279 
 Trusted the information given by  (name of program)?  1280 
 Found (name of program) easy  to use?  1281 
 Found (name of program) useful?  1282 
 Trusted the information given by  (name of program)?   1283 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 56 of 82  
 
 
 1284 
  1285 Timing  Escalation  De-escalation  
Visit 1 – Screening  and 
Questionnaires  Diabetes Specific Personality Questionnaire  
ABACUS  
Diabetes Locus of  Control  
Confidence in Diabetes Self -Care Scale  
Clarke's Hypoglycemia Awareness Scale  
Visit 2  – Study Equipment 
Training  None  
Final week of SAM  Run- in T1-Diabetes Distress Scale  
Hypoglycemia Fear Survey  
Hyperglycemia Avoidance Scale  
Visit 3 Eligibility Assessment, 
Randomization and Training  Pittsburgh Sleep Quality Index  
 Pittsburgh Sleep Quality Index  
Technology Expectations (burdens subscale only)  
INSPIRE  
DiAs Use in Phase 1 Mode  EMA Surveys  EMA Surveys  
Week 7 of DiAs Use in Phase 
1 Mode  Pittsburgh Sleep Quality  
Hyperglycemia Avoidance Scale  Technology Acceptance (burdens subscale only)  
Pittsburgh Sleep Quality Index  
T1-Diabetes Distress Scale  
Week 8 of DiAs Use in Phase 1 Mode  Confidence in Diabetes Self -Care  
T1-Diabetes Distress Scale  
Hypoglycemia Fear Survey  Hypoglycemia Fear Survey  
Hyperglycemia Avoidance Scale  
Confidence in Diabetes Self -Care Scale  
 
Visit 4 Phase 2 Initiation  Technology Expectations (burdens subscale only)  
INSPIRE (revised for DSS)  Technology Expectations (burdens subscale only)  
INSPIRE (revised for DSS)  
Diabetes Locus of Control  
DiAs Use in Phase 2 Mode  EMA Surveys  EMA Surveys  
Week 7 of DiAs Use in Phase 
2 Mode  Technology Acceptance (burdens subscale only)  
Pittsburgh Sleep Quality Index  
T1-Diabetes Distress Scale  
Week 8 of DiAs Use in Phase 
2 Mode  Hypoglycemia Fear  
Hyperglycemia Avoidance Scale  
Confidence in Diabetes Self -Care Scale  
 
Visit 5 Phase 3 Initiation  Technology Expectations (burdens subscale only)  
INSPIRE (revised for DSS)  
Diabetes Locus of Control  
 INSPIRE (revised for DSS)  
Diabetes Locus of Control  
DiAs Use in Phase 3 Mode  EMA Surveys  EMA Surveys  
Week 7 of DiAs Use in Phase 
3 Mode  Technology Acceptance (burdens subscale only) to 
assess patients’ experienced burdens related to 
the use of DSS  
Pittsburgh Sleep Quality Index (PSQI) to assess whether DSS improves sleep quality and quantity.  
 Pittsburgh Sleep Quality Index  
T1-Diabetes Distress Scale  
Week 8 of DiAs Use in Phase 
3 Mode  Hypoglycemia Fear Survey  
Hyperglycemia Avoidance  
Confidence in Diabetes Self -Care Scale  Hypoglycemia Fear Survey  
Hyperglycemia Avoidance Scale  
Confidence in Diabetes Self -Care Scale  
 Visit 6 Study Exit  ABACUS  
INSPIRE (revised for DSS)  
Diabetes Locus of Control  
 ABACUS  
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 57 of 82  
 
 Risks , Benefits, and Risk Assessment  1286 
 
 1287 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 1288 
handled to minimize this risk. Hypoglycemia, hyperglycemia and ketone formation are always a 1289 
risk in participants with T1DM  and participants will be monitored for these symptoms.  1290 
10.1.1.  Venipuncture Risks  1291 
A hollow needle will be placed in the arm for taking blood samples. Blood draws can cause some 1292 
common reactions like pain, bruising, or redness at the sampling site. Less common reactions 1293 
include bleeding from the sampling site, formation of a small blood clot or swelling of the vein 1294 
and surrounding tissues, and fainting.  1295 
There is the risk of contamination from blood sampling techniques. Hand washing with either 1296 
soap & water or waterless hand sanitizer will be used prior to caring for the study subject. Gloves 1297 
will be worn during blood sample collection and processing. Medical personnel will continue to 1298 
practice hygiene for the subject’s protection (i.e. hand washing, changing gloves frequently, 1299 
disposing needles properly). Gloves will be removed and hands washed or sanitized prior to 1300 
leaving and upon return to the subject’s room. Soiled linen will be changed to minimize the 1301 
transfer of pathogenic organisms.  1302 
10.1.2.  Fingerstick  Risks  1303 
About 2 drop of blood will be removed by fingerstick  for measuring blood sugars and sometimes 1304 
HbA1c or other tests. This is a standard method used to obtain blood for routine hospital 1305 
laboratory tests. Pain is common at the time of lancing. In about 1 in 10 cases, a small amount of 1306 
bleeding under the skin will produce a bruise. A small scar may persist for several weeks. The risk 1307 
of local infection is less than 1 in 1000. This should not be a significant contributor to risks in this 1308 
study as fingerstick s are part of the usual care for people with diabetes.  1309 
10.1.3.  Subcutaneous Catheter Risks  1310 
Participants using the study pump infusion sets will be at low risk for developing a local skin 1311 
infection at the site of the infusion set  placement. Though approved for 3 days of use, if a catheter 1312 
is left under the skin for more than 24 hours it is possible to get an infection where it goes into 1313 
the skin, with swelling, redness and pain. There may be bleeding where the catheter is put in and 1314 
bleeding under the skin causing a bruise (1 in 10 risk).  1315 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 58 of 82  
 10.1.4.  Sensor Needle Risks  1316 
Participants using the continuous glucose monitor ( CGM) with sensor will be at low risk for 1317 
developing a local skin infection at the site of the sensor needle placement. Though approved for 1318 
10 days of use, i f a catheter is left under the skin for more than 24 hours it is possible to get an 1319 
infection where it goes into the skin, with swelling, redness and pain. There may be bleeding 1320 
where the catheter is put in and bleeding under the skin caus ing a bruise (1 in 10 risk).  1321 
Study staff should verbally alert the participant that on rare occasions, the CGM may break and 1322 
leave a small portion of the sensor under the skin that may cause redness, swelling, or pain at 1323 
the insertion site. The participant should be further instructed to notify the study coordinator 1324 
immediately if this occurs.  1325 
10.1.5.  Risks of Hypoglycemia  1326 
As with any person having T1DM  and using insulin, there is always a risk of having a low blood 1327 
sugar (hypoglycemia). The frequency of hypoglycemia should be no more and possibly less than 1328 
it would be as part of daily living. Symptoms of hypoglycemia can include sweating, jitteriness, 1329 
and not feeling well. Just as at home, there is the possibility of fainting or seizures (convulsions) 1330 
and subsequently  for a few days the participant may not be as aware of symptoms of 1331 
hypoglycemia. A poorly functioning CGM can periodically display falsely high glucose values, 1332 
which could lead to inappropriate insulin recommendation.  1333 
10.1.6.  Risks of Hyperglycemia  1334 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 1335 
extended period or if the pump or infusion set is not working properly.  A poorly functioning CGM 1336 
can periodically display falsely high glucose values, which could lead to inappropriate insulin 1337 
recommendation.  1338 
10.1.7.  Risks of Device Reuse  1339 
Participant will be informed that FDA or relevant national authorities have approved the insulin 1340 
pump, CGM, glucometer and ketone meter for single use and that by using them among multiple 1341 
patients, bloodborne pathogens (i.e. Hepatitis B) may be spread through the use of multiple 1342 
users.  1343 
The study CGM system is label led for single use only. The sensor (the component of the system 1344 
that enters the skin) will be single use only. The transmitter and receiver may be reused during 1345 
the study after cleaning the device using a hospital -approved cleaning procedure. The transmitter 1346 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 59 of 82  
 is attached to the sensor but does not enter the skin and the receiver, if used, is a hand held 1347 
device.  1348 
The study insulin pump s are labell ed for single -patient use. During the study, this device may be 1349 
reused after  adhering to a hospital- approved cleaning procedure. All infusion set equipment will 1350 
be single patient use only (infusion set insertion kits, tubing, cartridges etc.) . 1351 
10.1.8.  Other Risks  1352 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 1353 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  1354 
If these reactions occur, different adhesives or “under -taping” (such as with IV 3000, Tegaderm, 1355 
etc.) will be tried, sites will be rotated frequently, and a mild topical steroid cream or other 1356 
medication may be required.  1357 
Whenever the skin is broken there is the possibility of an infection. The CGM and pump infusion 1358 
sites are inserted under the skin. It is possible that any part that is inserted under the skin may 1359 
cause an infection. These occur very infrequently, but, if an infection was to occur, oral and/or 1360 
topical antibiotics can be used. The risk of skin problems could be greater if you use a sensor for 1361 
longer than it is indicated for  use. Therefore, participants will be carefully instructed about proper 1362 
use of the sensor.  1363 
 
 1364 
It is expected that this protocol will yield increased knowledge about using a Decision Support 1365 
System for insulin dosing suggestions. The individual participant may or may not benefit from 1366 
study participation.  1367 
 
 1368 
Based on the facts that (1) adults with diabetes experience mild hypoglycemia and hyperglycemia 1369 
frequently as a consequence of the disease and its management, (2) the study intervention 1370 
involves feedback and advice for insulin dosing that may increase the likelihood of hypoglycemia, 1371 
and hyperglycemia, (3) mitigations are in place, and have been tested in prior studies using the 1372 
investigational device system in the home setting . . 1373 
 
 1374 
The study is being conducted in compliance with the policies described in the study policies 1375 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with 1376 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  1377 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 60 of 82  
 Whenever possible, data will be directly collected in electronic case report forms, which will be 1378 
considered the source data.    1379 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 61 of 82  
 
 Device Cleaning Instructions  1380 
CGM cleaning instructions are provided in the Dexcom G4 PLATINUM (Professional) Cleaning and 1381 
Disinfection manual (current edition). The transmitter will  be cleaned with Clorox Healthcare® 1382 
Bleach Germicidal Cleaner or any disinfectant product in a spray bottle containing a bleach 1383 
solution of 6500 parts per million with the EPA registration number 56392 -7. The transmitter will 1384 
be submerged in this solution and then placed on an absorbent wipe or clean surface. Two sprays 1385 
will be dispensed from the Clorox cleaner onto each side of the transmitter. A nylon brush will 1386 
be used to scrub the transmitter on all sides for 30 seconds. The transmitter will be placed in the 1387 
Clorox Cleaner solution for one minute. The t ransmitter is then rinsed under flowing tap water 1388 
for ten seconds. The transmitter will then be disinfected using a disinfectant product with EPA 1389 
registration number 56392 -7 using similar procedures as the cleaning process.   1390 
Per the pump manufacturer, the insulin pump will be cleaned with a damp lint -free cloth. Use of 1391 
household or industrial cleaners, sol vents, bleach, scouring pads, chemi cals, or sharp instruments 1392 
are prohibited. The pump should never be submerged in water. If needed, a very mild detergent, 1393 
such as a bit of liq uid soap with warm water  will be used . A soft towel will be used to dry the 1394 
pump.  1395 
Equipment that touches intact skin will be cleaned with ethyl or isopropyl alcohol (70 -90%), 1396 
quaternary ammonium germicidal detergent (i.e. Cavicide, EPA number 46781) or household 1397 
bleach. The contact time on the surface depends on the method used to clean the equipment. 1398 
Cavicide requires three minutes on the surface of the equipment. Clorox Germicidal Bleach Wipes 1399 
require two minutes on the equipment. The surface should remain wet (i.e. slightly damp) with 1400 
the disinfectant to be considered effective though not wet enough to leave drops of liquid.  1401 
In the event a manufacturer update  for cleaning procedures of their device, the study team will 1402 
adhere to the most current recommendations.   1403 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 62 of 82  
 
 Adverse Events, Device Issues, and Stopping Rules  1404 
The protocol is considered a significant risk device study due to the fact that the closed loop 1405 
system is experimental. Therefore, an investigational device exemption (IDE) from the U.S. Food 1406 
and Drug Administration (FDA) is required to conduct the study.  1407 
 
 1408 
12.1.1.  Adverse Events (AE)  1409 
A reportable adverse event includes any untoward medical occurrence that meets one of the 1410 
following criteria:  1411 
• A Serious Adverse Event  as defined in section 12.1.2  1412 
• An Adverse Device Effect as defined in section 12.1.4, unless excluded from reporting in 1413 
section 12.8  1414 
• An Adverse Event as defined in section 12.1.4 occurring in association with a study 1415 
procedure  1416 
• An AE as defined in section 12.1.1 which leads to discontinuation of  a study device for 2 1417 
or more hours  1418 
• Hypoglycemia meeting the definition of severe hypoglycemia as defined in section 12.3.1   1419 
• Diabetic ketoacidosis (DKA) as defined in section 12.3.2 or in the absence of DKA, a 1420 
hyperglycemic or ketosis event meeting the criteria defined below  1421 
Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse 1422 
events unless associated with an Adverse Device Effect. Skin reactions from sensor placement 1423 
are only reportable if severe and/or required treatment.  1424 
12.1.2.  Serious  Adverse Event (SAE)  1425 
 Any untoward medical occurrence that:  1426 
• Results in death.  1427 
• Is life -threatening; (a non -life-threatening event which, had it been more severe, might 1428 
have become life- threatening, is not necessarily considered a serious adverse event).  1429 
• Requires inpatient hospitalization or prolongation of existing hospitalization.  1430 
• Results in persistent or significant disability/incapacity or substantial disruption of the 1431 
ability to conduct normal life functions ( life threatening).  1432 
• Is a congenital anomaly or birth defect.  1433 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 63 of 82  
 • Is considered a significant medical event by the investigator based on medical judgment 1434 
(e.g., may jeopardize the participant or may require medical/surgical intervention to 1435 
prevent one of the outcomes listed above).  1436 
12.1.3.  Unanticipated Adverse Device Effect (UADE)  1437 
Any serious adverse effect on health or safety or any life- threatening problem or death caused 1438 
by, or associated with a device, if that effect, problem, or death was not previously identified in 1439 
nature, severity, or degree of incidence in the investigational plan or application (including a 1440 
supplementary plan or application), or any other unanticipated serious problem associated with 1441 
a device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)).  1442 
12.1.4.  Adverse Device Effect (ADE)  1443 
Any untoward medical occurrence in a study participant which the device may have caused or to 1444 
which the device may have contributed . 1445 
12.1.5.  Device Complaints and Malfunctions  1446 
A device complication or complaint is something that happens to a device or related to device 1447 
performance, whereas an adverse event happens to a participant.  A device complaint may occur 1448 
independently from an AE, or along with an AE. An AE may occur without a device complaint or 1449 
there may be an AE related to a device complaint. A device malfunction is any failure of a device 1450 
to meet its performance specifications or otherwise perform as intended. Performance 1451 
specifications include all claims made in the labeling for the device.  The intended performance 1452 
of a device refers to the intended use for which the device is labeled or marketed. (21 CFR 803.3).   1453 
 
 1454 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practices 1455 
(GCP), or procedure requirements. The noncompliance may be either on the part of the 1456 
participant, the investigator, or the study site staff. As a result of deviations, corrective actions 1457 
may be developed by the site and implemented as appropriate. Major deviations will be reported 1458 
to the IRB -HSR within 7 calendar days of when the study team becomes aware of the event.  1459 
 
 1460 
12.3.1.  Hypoglycemia Event  1461 
Hypoglycemia not associated with an Adverse Device Effect is only reportable as an adverse event 1462 
when the following definition for severe hypoglycemia is met:  1463 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 64 of 82  
 • The event required assistance of another person due to altered consciousness, and 1464 
required another person to actively administer carbohydrate, glucagon, or other 1465 
resuscitative actions;  1466 
• Impaired cognitively to the point that he/she was unable to treat himself/herself, was 1467 
unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or 1468 
experienced seizure or coma. These episodes may be associated with sufficient 1469 
neuroglycopenia to induce seizure or coma;  1470 
• If plasma glucose measurements are not available during such an event, neurological 1471 
recovery attributable to the restoration of plasma glucose to normal is considered 1472 
sufficient evidence that the event was induced by a low plasma glucose concentration.  1473 
12.3.2.   Hyperglycemia Events/Diabetes Ketoacidosis  1474 
Hyperglycemia not associated with an Adverse Device Effect is only reportable as an adverse 1475 
event when one of the following four  criteria is met . 1476 
The event involved DKA, as defined by the Diabetes Control and Complications Trial (DCCT) and 1477 
described below: 1478 
• Evaluation or treatment was obtained at a health care provider facility for an acute event 1479 
involving hyperglycemia or ketosis  1480 
• Blood ketone level ≥1.5 mmol/L and communication occurred with a health care provider 1481 
at the time of the event  1482 
• Blood ketone level ≥3.0 mmol/L, even if there was no communication with a health care 1483 
provider  1484 
• Hyperglycemic events are classified as DKA if the following are present:  1485 
o Symptoms such as polyuria, polydipsia, nausea, or vomiting;  1486 
o Serum ketones ≥1.5 mmol/L or large/moderate urine ketones;  1487 
o Treatment provided in a health care facility  1488 
All reportable Adverse Events —whether volunteered by the participant, discovered by study 1489 
personnel during questioning, or detected through physical examination, laboratory test, or 1490 
other means —will be reported on an adverse event form online. Adverse event s  will be 1491 
presented to the DSMB in accumulated manner during each meeting.  1492 
 
 1493 
The study investigator will assess the relationship of any adverse event to be related or unrelated 1494 
by determining if there is a reasonable possibility that the adverse event may have been caused 1495 
by the study device.  1496 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 65 of 82  
 To ensure consistency of adverse event causality assessments, investigators should apply the 1497 
following general guideline when determining whether an adverse event is related:  1498 
• There is a plausible temporal relationship between the onset of the adverse event and 1499 
the study intervention, and the adverse event cannot be readily explained by the 1500 
participant’s clinical state, intercurrent illness, or concomitant therapies; and/or the 1501 
adverse event follows a known pattern of response to the study intervention; and/or the 1502 
adverse event abates or resolves upon discontinuation of the study intervention or dose 1503 
reduction and, if applicable, reappears upon re -challenge.  1504 
• Evidence exists that the adverse event has an etiology other than the study intervention 1505 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, or 1506 
concomitant medication); and/or the adverse event has no plausible temporal 1507 
relationship to study intervention. 1508 
 
 1509 
The intensity of an adverse event will be rated on a three point scale: (1) mild, (2) moderate, or 1510 
(3) severe. It is emphasized that the term severe is a measure of intensity: thus, a severe adverse 1511 
event is not necessarily serious. For example, itching for several days may be rated as severe, but 1512 
may not be clinically serious.  1513 
• MILD:  Usually transient, requires no special treatment, and does not interfere with the 1514 
participant’s daily activities.  1515 
• MODERATE:  Usually causes a low level of inconvenience or concern to the participant and 1516 
may interfere with daily activities, but is usually ameliorated by simple therapeutic 1517 
measures.  1518 
• SEVERE:  Interrupts a participant’s usual daily activities and generally requires systemic 1519 
drug therapy or other treatment.  1520 
 
 1521 
Adverse events will be coded per the UVA IRB website instructions (i.e. mild, moderate, severe).    1522 
Adverse events that continue after the participant’s discontinuation or completion of the study 1523 
will be followed until their medical outcome is determined or until no further change in the 1524 
condition is expected.  1525 
 
 1526 
The outcome of each reportable adverse event will be classified by the investigator as follows:  1527 
• RECOVERED/RESOLVED  – The participant recovered from the AE/SAE without sequelae.  1528 
Record the AE/SAE stop date.  1529 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 66 of 82  
 • RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized 1530 
without change in the event anticipated. Record the AE/SAE stop date.  1531 
• FATAL – A fatal outcome is defined as the SAE that resulted in death. Only the event that 1532 
was the cause of death should be reported as fatal. AEs/SAEs that were ongoing at the 1533 
time of death; however, were not the cause of death, will be recorded as “resolved” at 1534 
the time of death.  1535 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the 1536 
event was ongoing with an undetermined outcome.  1537 
• An ongoing outcome will require follow- up by the site in order to determine the final 1538 
outcome of the AE/SAE.  1539 
• The outcome of an ongoing event at the time of death that was not the cause of death, 1540 
will be updated and recorded as “resolved” with the date of death recorded as the stop 1541 
date.  1542 
• UNKNOWN – An unknown outcome is defined as an inability to access the participant or 1543 
the participant’s records to determine the outcome (for example, a participant that was 1544 
lost to follow -up). 1545 
All clinically significant abnormalities of clinical laboratory measurements or adverse events 1546 
occurring during the study and continuing at study termination should be followed by the 1547 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the 1548 
underlying cause, or resolution. Follow -up information should be recorded on source documents.  1549 
If any reported adverse events are present when a participant completes the study, or if a 1550 
participant is withdrawn from the study due to an adverse event, the participant will be 1551 
contacted for re -evaluation. If the adverse event has not resolved, additional follow -up will be 1552 
performed as appropriate. Every effort should be made by the Investigator or delegate to contact 1553 
the participant until the adverse event has resolved or stabilized.  1554 
 
 1555 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 1556 
whether an adverse event occurred, except in the following circumstances.   1557 
The following device issues are anticipated and will not be reported but will reported as an 1558 
Adverse Event if the criteria for AE reporting described above are met:  1559 
• Component disconnections  1560 
• CGM sensors lasting fewer than the number of days expected per CGM labeling  1561 
• CGM tape adherence issues  1562 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 67 of 82  
 • Pump infusion set occlusion not leading to ketosis  1563 
• Battery lifespan deficiency due to inadequate charging or extensive wireless 1564 
communication  1565 
• Intermittent device component disconnections/communication failures not leading to 1566 
system replacement  1567 
• Device issues clearly addressed in the user guide manual that do not require additional 1568 
troubleshooting  1569 
• Skin reactions from CGM sensor placement or pump infusion set placement that do not 1570 
meet criteria for AE reporting  1571 
 
 1572 
• UADEs must be reported within 10 working days to the FDA  after the sponsor first 1573 
receives notice of the adverse effect.  1574 
• Other reportable adverse events, device malfunctions (with or without an adverse event) 1575 
and device complaints should be reported promptly, but there is no formal required 1576 
reporting period.  1577 
• The IDE Sponsor will investigate the UADE and if indicated, report the results of the 1578 
investigation to the IRBs, FDA, and DSMB  will within 10 working days of the study team  1579 
becoming aware of the UADE per 21CFR 812.46(b).  1580 
• The DSMB  will determine if the UADE presents an unreasonable risk to participants. If so, 1581 
the DSMB  will must ensure that all investigations, or parts of investigations presenting 1582 
that risk, are terminated as soon as possible but no later than 5 working  days after the 1583 
DSMB  will makes this determination and no later than 15 working  days after first receipt 1584 
notice of the UADE.  1585 
• In the case of a device system component malfunction (e.g. pump, CGM, control 1586 
algorithm), information will be forwarded to the responsible manufacturer by the study 1587 
personnel . 1588 
 
 1589 
An independent Data and Safety Monitoring Board (DSMB) will be  establish to review compiled 1590 
safety data at periodic intervals to oversee and monitor our randomized clinical trial to ensure 1591 
the safety of participants, as well as the validity and integrity of the data.   1592 
Details regarding membership, meetings, responsibilities will be documented in a separate DSMB 1593 
Charter.  1594 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 68 of 82  
 
 
 1595 
12.11.1.  Participant Discontinuation  1596 
Rules for discontinuing study device use are : 1597 
• The investigator believes it is unsafe for the participant to continue on the intervention.  1598 
This could be due to the development of a new medical condition or worsening of an 1599 
existing condition; or participant behavior contrary to the indications for use of the device 1600 
that imposes on the participant’s safety  1601 
• The participant requests that the treatment be stopped  1602 
• Two distinct episodes of DKA  1603 
• Two distinct severe hypoglycemia events  as defined in section 12.3.1  1604 
12.11.2.  Suspending/Stopping Overall Study  1605 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1606 
hyperglycemia event, use of the study device system will be suspended while the problem is 1607 
diagnosed.  1608 
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1609 
study device requires stoppage of device use for safety reasons (e.g. product recall). The affected 1610 
study activities may resume if the underlying problem can be corrected by a protocol or system 1611 
modification that will not invalidate the results obtained prior to suspension.  1612 
 
 1613 
A Medical Monitor will  review all DKA and severe hypoglycemia irrespective of relatedness to 1614 
study device use, and all serious events (including UADEs) related to study device use at the time 1615 
of occurrence. The Medical Monitor  can request modifications to the study protocol or 1616 
suspension or outright stoppage of the study if deemed necessary based on the totality of safety 1617 
data available. Details regarding Medical Monitor review will be documented in a separate 1618 
Medical Monitor  document.     1619 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 69 of 82  
 
 Miscellaneous Considerations  1620 
 
 1621 
Participants using glulisine at the time of enrollment will be asked to contact their personal 1622 
physician to change their prescribed personal insulin to lispro or aspart for the duration of the 1623 
trial.  1624 
The study devices (study insulin pump, study CGM) must be removed before Magnetic Resonance 1625 
Imaging (MRI), Computed Tomography (CT) or diathermy treatment. Participants may continue 1626 
in the trial after temporarily discontinuing use if requiring one of the treatments above.  1627 
 
 1628 
Participation in the study is voluntary. P articipant may withdraw at any time. For  participants 1629 
who do withdraw  from the study, the study team will determine if their data will be used in 1630 
analysis.  1631 
 
 1632 
For security and confidentiality purposes, subjects will be assigned an identifier that will be used 1633 
instead of their name. Protected health information gathered for this study may be shared with 1634 
the third -party collaborators. De -identified subject information may also be provided to 1635 
collaborators involved in the study after the appropriate research agreement has been executed.    1636 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 70 of 82  
 
 Statistical Consideration  1637 
 
 1638 
This is a randomized crossover study in T1DM designed to demonstrate the efficacy of 1639 
personalized feedback (PF) and decision support (DSS) over sensor -augmented pump ( SAM ) 1640 
therapy and to establish relationships between the level of glucose variability (GV) control 1641 
achievable by the intervention and individual psycho -behavioral characteristics.  1642 
We plan to split the study into 4 cohorts of about 25 participants each (expected retention 20 1643 
per cohort). Each cohort will continue for ~7 months and will have the structure presented in 1644 
Figure 5 . Following recruitment, screening, and a run -in period of SAM , participants will be 1645 
randomized into one of two groups: escalation vs. de -escalation of devices and function. Each 1646 
treatment modality ( SAM , PF, DSS) will continue for about 8 weeks, with the last 4 weeks used 1647 
to assess GV from CGM data.  1648 
Escalation: SAM  → PF → DSS  1649 
De-escalation: DSS → PF → SAM  1650 
 
 1651 
14.2.1.  Sample Size D etermination:  1652 
Sample size determination  is based on our related pilot studies of DSS. We estimate that the 1653 
effect size of DSS vs. SAM  will be  f³0.22. Power calculations (G*Power 3.1.9.2) assuming a=0.017 1654 
(corrected for multiple comparisons), 95% power, correlation of 0.55 between the repeated 1655 
measures, and attrition of 20%, yield a sample size of N=100 subjects to be randomized at 1656 
baseline, with N=80 subjects completing the study. PF vs. SAM  assumes the same effect size. We 1657 
expect that while overall DSS effect vs. PF will be smaller than vs. SAM , GV control over time will 1658 
be more consistent. Aim 1.3 analysis therefore assumes a small effect size (0.15) but 5 repeated 1659 
measures (bi -weekly) in each condition with higher correlation (0.65), leading to an achieved 1660 
power of 97.2% for this Aim.  1661 
14.2.2.  Exploration of the effect of treatment escalation vs. de- escalation:  1662 
A key advantage of the proposed study design (beyond the optimal statistical power) is the 1663 
possibility to explore the glucose control and psycho -behavioral impact of features being added 1664 
and/or enhanced with prescriptive components (DSS), vs. features being limited to information 1665 
(PF) or even removed ( SAM ). We will perform this analysis by looking at the between factors in 1666 
the repeated ANOVA analysis, contrasting the escalation group vs. de -escalation group. While 1667 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 71 of 82  
 not powered , this analysis will provide key insights in the future feature adaptation schemes 1668 
based on the ATI.   1669 
 
 1670 
 Glycemic outcomes: 1671 
The primary outcome of this study will be Glucose Variability (GV) as measured by CGM- based 1672 
Coefficient of Variation (CV), as recommended by the International Consensus on Use of 1673 
Continuous Glucose Monitoring. To further characterize glucose control, we will compute other 1674 
CGM Consensus outcomes as well:   1675 
• Average   1676 
• Percent in different ranges:   1677 
o <50 mg/dL   1678 
o <54 mg/dL   1679 
o <60 mg/dL   1680 
o <70 mg/dL   1681 
o ≤70-≤180 mg/dL   1682 
o >180 mg/dL   1683 
o >250 mg/dL   1684 
o >300 mg/dL   1685 
• SD and coefficient of variation  1686 
• LBGI, HBGI, ADRR  1687 
Each modality of treatment will be assessed using the last 4 weeks of CGM recordings, as we 1688 
expect most of the GV benefits of each intervention to be realized within the first 4 weeks of the 1689 
intervention, and a minimum of 24 days of data is considered optimal for CGM –based CV 1690 
determination.   1691 
14.3.2.  Glucose Variability Reduction Achieved with CGM -based expert systems:   1692 
General linear models (GLM) (repeated measu res ANOVA) will be used to assess the significance 1693 
of the differences in average response between SAM , PF, and DSS  across appropriate CGM -based 1694 
metrics. The particular design  of the clinical study allow for Aims 1.1, 1.2, and 1.3 to each be 1695 
addressed independently in a randomized crossover analysis, as sho wn in Figure 4 . While the 1696 
randomized order of the interventions (escalation vs de -escalation) allows for an objective 1697 
assessment of the average efficacy of each of them, we will introduce the order as a fixed factor 1698 
to verify if significant study effects can be detected. Finally, we will study the evolution of GV 1699 
within each modality period: GV and other CGM -based outcomes will be computed bi -weekly 1700 
(the minimum length of time for precise GV assessment) and entered in a repeated measures 1701 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 72 of 82  
 GLM analysis; within -subject contrast (linear and polynomial) using 5 repeated measures per 1702 
condition to explore the evolution of the glycemic outcomes in time; Aim 1.3 .  1703 
 
 1704 
A key advantage of the proposed study design (beyond the optimal statistical power) is the 1705 
possibility to explore the glucose control and psycho -behavioral impact of features being added 1706 
and/or enhanced with prescriptive components (DSS), vs. fea tures being limited to information 1707 
(PF) or even removed ( SAM ). We will perform this analysis by looking at the between factors in 1708 
the repeated ANOVA analysis, contrasting the escalation group vs. de -escalation group. While 1709 
not powered, this analysis will provide key insights in the future feature adaptation schemes 1710 
based on the ATI.  1711 
 
 1712 
Quantitative data on usability and satisfaction will be analyzed using simple descriptive statistics. 1713 
In addition, we will analyze scores from the measures in the psychosocial assessment battery to 1714 
determine if changes occur over time and between groups. Using SPSS 26 , we will construct 1715 
predictive models in the general linear modeling (GLM) framework to examine each set of 1716 
psychological factors (e.g., INSPIRE survey) over time, and their  association with glycemic  1717 
outcomes. Group assignment  and Study Phases  will be the primary covariate.  1718 
 
 1719 
Baseline demographic and clinical characteristics of the cohort of all randomized participants will 1720 
be summarized in a table using summary statistics appropriate to the distribution of each 1721 
variable. Descriptive statistics will be displayed overall and by treatment group.  1722 
Will include:  1723 
• Age 1724 
• HbA1c  collected at randomization and study end  1725 
• Gender  1726 
• Race/ethnicity  1727 
• CGM use before enrollment  1728 
• Diabetes duration  1729 
• BMI 1730 
 
 1731 
We will count each time the participant interacted with the study Personalized Feedback and 1732 
Decision Support System  and perform a Wilcoxon paired rank test to determine if any differences 1733 
exist in system interactions .   1734 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 73 of 82  
 
 Data Collection and Monitoring 1735 
 
 1736 
The study data are collected through a combination of case report forms (electronic and paper) 1737 
and electronic device data files obtained from the software and individual hardware 1738 
components. These electronic device files and electronic CRFs are considered the primary source 1739 
documentation.  1740 
When data are directly collected in electronic case report forms, this will be considered the 1741 
source data. Records will be maintained in accordance with ICH E6 and institutional regulatory 1742 
requirements for the protection of confidentiality of participants. 1743 
 
 1744 
Study documents will  be retained for a minimum of 2 years after study close out. These 1745 
documents may  be retained for a longer period, however, if required by local regulations. No 1746 
records will b e destroyed without the consent of the Principal Investigator. It is the responsibility 1747 
of the Principal Investigator to inform all co -investigator s when these documents no longer need 1748 
to be retained.   1749 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 74 of 82  
 
 Ethics/Protection of Human Participants  1750 
 
 1751 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1752 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1753 
CFR Part 56, and/or the ICH E6.  1754 
 
 1755 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 1756 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 1757 
form must be obtained before any participant is enrolled. Any amendment to the protocol will 1758 
require review and approval by the IRB before the changes are implemented to the study. All 1759 
changes to the consent form will be IRB approved; a determination will be made regarding 1760 
whether previously consented participants need to be re -consented.  1761 
 
 1762 
Informed consent is a process that is initiated prior to an individual’s agreement to participate in 1763 
the study and continues throughout the individual’s study participation. Extensive discussion of 1764 
risks and possible benefits of participation will be provided. Consent forms will be IRB approved 1765 
and the participant will be asked to read and review the document. The investigator or their 1766 
delegate will explain the research study to the participant  and answer any questions that may 1767 
arise. All participants will receive a verbal explanation in terms suited to their comprehension of 1768 
the purposes, procedures, and potential risks of the study and of their rights as research 1769 
participants. P articipant s will have the opportunity to carefully review the written consent form 1770 
and ask questions prior to signing.  1771 
The participant will sign the informed consent document prior to any procedures being do ne 1772 
specifically for the study. A copy of the informed consent document will be given to the 1773 
participant for their records. The rights and welfare of the participants will be protected by 1774 
emphasizing to them that the quality of their medical care will not be adversely affected if they 1775 
decline to participate in this study.  1776 
 
 1777 
The study monitor, representatives of the IRB or device company supplying study product may 1778 
inspect all documents and records required to be maintained by the investigator, including but 1779 
not limited to, medical records (office, clinic, or hospital) for the participants in this study.   1780 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 75 of 82  
 The study participant’s contact information will be securely stored at the clinical site for internal 1781 
use during the study. At the end of the study, all records will continue to be kept in a secure 1782 
location for as long a period as dictated by local IRB and Institutional regulations.  1783 
Study participant research data, which is for purposes of statistical analysis and scientific 1784 
reporting, will be stored at the University of Virginia Center for Diabetes Technology.  The study 1785 
data entry and study management systems used by research staff will be secured and password 1786 
protected. At the end of th e study, all study databases may  be de -identified and archived at the 1787 
University of Virginia Center for Diabetes Technology.   1788 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 76 of 82  
 
 References  1789 
1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes 1790 
care. 2014 Jan 1;37(Supplement 1):  S81- 90. 1791 
2. Hirsch IB. Insulin analogues. New England Journal of Medicine. 2005 Jan 13;352(2):174 - 1792 
83. 1793 
3. Klonoff DC, Prahalad P. Performance of cleared blood glucose monitors. Journal of 1794 
diabetes science and technology. 2015 Jun 30;9(4):895 -910.  1795 
4. Castle JR, Jacobs PG. Nonadjunctive use of continuous glucose monitoring for diabetes 1796 
treatment decisions. Journal of diabetes science and technology. 2016 Sep;10(5):1169 - 1797 
73. 1798 
5. Diabetes Control and Complications Trial. Intensive diabetes treatment and 1799 
cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 1800 
22;2005(353):2643- 53. 1801 
6. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All -cause mortality trends in a 1802 
large population -based cohort with long -standing childhood- onset type 1 diabetes. 1803 
Diabetes care. 2010 Dec 1;33(12):2573 -9. 1804 
7. Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, 1805 
Clements M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. New 1806 
England Journal of Medicine. 2014 Nov 20;371(21):1972- 82. 1807 
8. Nishimura R, LaPorte RE, Dorman JS, Tajima N, Becker D, Orchard TJ. Mortality trends in 1808 
type 1 diabetes. Diabetes care. 2001 May 1;24(5):823 -7. 1809 
9. McCall AL, Kovatchev BP. The Median is Not the Only Message: A Clinician's Perspective 1810 
on Mathematical Analysis of Glycemic Variability and Modeling in Diabetes Mellitus. J 1811 
Diabetes Sci Technol  3: 3-11, 2009.  1812 
10. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, DCCT/EDIC Research Group: 1813 
Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes 1814 
Control and Complications Trial Revisited. Diabetes , 57: 995- 1001, 2008.  1815 
11. Santiago JV. Lessons from the Diabetes Control and Complications Trial, Diabetes , 1816 
42:1549 -1554, 1993.  1817 
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive 1818 
treatment of diabetes on the development and progression of long -term complications 1819 
of insulin -dependent diabetes mellitus. N Engl J Med 329: 978 -986, 1993.  1820 
13. UK Prospective Diabetes Study Group (UKPDS). Intensive blood- glucose control with 1821 
sulphonylureas or insulin compared with conventional treatment and risk of 1822 
complications in patients with type 2 diabetes.  Lancet  352: 837- 853, 1998.  1823 
14. American Diabetes Association Workgroup on Hypoglycemia (Childs BP, Clark NG, Cox DJ, 1824 
Cryer PE, Davis SN, Di -Nardo MM, Kahn R, Kovatchev BP, Shamoon H). Defining and 1825 
Reporting Hypoglycemia in Diabetes. Diabetes Care , 28:1245- 1249, 2005.  1826 
15. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in Diabetes. Diabetes Care , 26: 1902 -1912, 1827 
2003.  1828 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 77 of 82  
 16. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the 1829 
Diabetes Control and Complications Trial. Diabetes  46: 271- 286, 1997.  1830 
17. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type I and 1831 
type II diabetes. Diabetologia  45: 937- 948, 2002.  1832 
18. Cryer PE: Hypoglycemia: The Limiting factor in the management of IDDM. Diabetes  43: 1833 
1378- 1389, 1994.  1834 
19. The Diabetes Control and Complications Trial Research Group: The relationship of 1835 
glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in 1836 
the Diabetes Control and Complications Trial. Diabetes  44:968– 983, 1995.  1837 
20. Brownlee M, Hirsh IB.  Glycemic Variability: A hemoglobin A1c –Independent Risk Factor 1838 
for Diabetic Complication?  JAMA,  295: 1707 -1708, 2006.  1839 
21. Hirsh IB, Brownlee M: Should minimal blood glucose variability become the gold standard 1840 
of glycemic control? J Diabetes Complications , 19:178– 181, 2005.  1841 
22. Esposito K, Giugliano D, Nappo F, Martella K, for the Campanian Postprandial 1842 
Hyperglycemia Study Group. Postprandial Hyperglycemia Study Group.  Regression of 1843 
carotid atherosclerosis by control of postprandial hyperglycemiain type 2 diabetes 1844 
mellitus . Circulation  110: 214 -219, 2004.  1845 
23. Haffner S.M. The importance of postprandial hyperglycaemia in development of 1846 
cardiovascular disease in people with diabetes: International Journal of Clinical Practice . 1847 
Supplement 123:  24-26, 2001.  1848 
24. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of Oxidative 1849 
Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in 1850 
Patients With Type 2 Diabetes.  JAMA  2006 295: 1681 -1687.  1851 
25. Temelkova -Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. 1852 
Postchallenge Plasma Glucose and Glycemic Spikes are More Strongly Associated With 1853 
Atherosclerosis Than Fasting Glucose or HbA1c Level. Diabetes Care , 23:1830– 1834, 2000.  1854 
26. Waldhäusl WK. The physiological basis of insulin treatment —clinical aspects. 1855 
Diabetologia. 1986 Dec 1;29(12):837- 49. 1856 
27. Grunberger G, Abelseth JM, Bailey TS, et al Consensus statement by the American 1857 
Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump 1858 
Management Task Force. Endocr Pract 2014;20:463– 89. 1859 
28. YB Kim and J. Lee, “Smart Devices for Older Adults Managing Chronic Disease: A Scoping 1860 
Review,” JMIR Mhealth and Uhealth, 5(5):e69, 2017.  1861 
29. K. Singh, K. Drouin, L. P. Newmark, et al., “Patient- Facing Mobile Apps to Treat High -Need, 1862 
High -Cost Populations: A Scoping Review,” JMIR Mhealth and Uhealth, 4(4):e316, 2016.  1863 
30. N. Kaufman and A. Salahi, “Using Digital Health Technology to Prevent and Treat 1864 
Diabetes,” Diabetes Technology & Therapeutics, 19(Supplement 1):59 -73. 1865 
31. H. D. Lehmkuhl et al., “Telehealth Behavior Therapy for the Management of Type 1 1866 
Diabetes in Adolescents,” J. Diabetes Science and Technology, 4(1):199 -208, 2010.  1867 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 78 of 82  
 32. C. L. Wood, et al., “Use of Telemedicine to Improve Adherence to American Diabetes 1868 
Association Standards in Pediatric Type 1 Diabetes,” Diabetes Technology & Therapeutics, 1869 
18(1):7- 14, 2016.  1870 
33. B. P. Kovatchev, P. Mendosa, S. Anderson, J. S. Hawley, L. M. Ritterband, L. Gonder - 1871 
Frederick, “Effect of Automated Bio -Behavioral Feedback on the Control of Type 1 1872 
Diabetes,” Diabetes Care, 34:302 -307, 2011.  1873 
34. D. C. Klonoff and D. Kerr, “Digital Diabetes Communication: There’s an App for That,” J. 1874 
Diabetes Science and Technology, 10(5):1003 -1005, 2016.  1875 
35. H. Zisser, L. Jovanovic, F. J. Doyle III, P. Ospina, and  C. Owens. Run -to-run control of meal - 1876 
related insulin dosing. Diab Technol Ther, 7:48 –57, 2005.  1877 
36. C. Owens, H. Zisser, L. Jovanovic, B. Srinivasan, D. Bonvin, and F. J. Doyle III. Run -to-run 1878 
control of blood glucose concentrations for people with type 1 diabetes mellitus. IEEE 1879 
Trans Biomed Eng, 53:996– 1005, 2006  1880 
37. P. Herrero, P. Pesl, M. Reddy, N. Oliver, P. Georgiou, and  C. Toumazou. Advanced insulin 1881 
bolus advisor based on run- to-run control and case -based reasoning. IEEE Journal of 1882 
Biomedical and Health Informatics, 19(3):1087 –1096, 2015.  1883 
38. C.C. Palerm, H. Zisser, W.C. Bevier, L. Jovanovic, and F. J. Doyle III. Prandial insulin dosing 1884 
using run- to-run control: application of clinical data and medical expertise to define a 1885 
suitable performance metric. Diabetes Care, 30:1131 –1136, 2007.  1886 
39. C.C. Palerm, H. Zisser, L. Jovanovic, and F. J. Doyle III. A run -to-run control strategy to 1887 
adjust basal insulin infusion rates in type 1 diabetes. J Process Control, 18:258 –265, 2008.  1888 
40. L. Kennedy and A. Brown, “FDA Clears ‘My Dose Coach’ App to Optimize Basal Insulin 1889 
Dosing,” diaTribe: Making Sense of Diabetes, (https://diatribe.org/fda- clears -my-dose - 1890 
coach -app-to-optimize -basal- insulin -dosing), posted April 2017.  1891 
41. S. D. Patek, D. Lv, E. Campos -Nanez, M. Breton, “Retrospective Optimization of Daily 1892 
Insulin Therapy Parameters: Control Subject to a Regenerative Disturbance Process,” IFAC 1893 
Symposium on Dynamics and Control of Process Systems, IFAC -PapersOnLine 49 -7, pp. 1894 
773-778, 2016.  1895 
42. C. Toffanin, A. Sandri, M. Messori, C. Cobelli, and L. Magni. Automatic adaptation of basal 1896 
therapy for type 1 diabetic patients: a run -to-run approach. In IFAC 19th World Congress, 1897 
pages 2070– 2075, 2014.  1898 
43. Steil GM, Oladunjoye AO, Wald JS, Slyne C, Atakov -Castillo A, Greenberg J, Greaves T, 1899 
Toschi E, Munshi M. Use of Automated Clinical Decision Support (CDS) to Effect Glycemic 1900 
Control in Elderly Patients with T1D.  1901 
44. J. Tuo et al., “Optimization of insulin pump therapy based on high order run -to-run control 1902 
scheme,” Comput Methods Programs Biomed, 120(123 -134), 2015.  1903 
45. Doyle FJ, 3rd, Huyett LM, Lee JB, Zisser HC, Dassau E. Closed -loop artificial pancreas 1904 
systems: engineering the algorithms. Diabetes care 2014;37:1191 -7. 1905 
46. Hovorka, R et al. Manual closed -loop insulin delivery in children and adolescents with 1906 
Type 1 Diabetes: A phase 2 randomised crossover trial. The Lancet,  375, 743- 751 (2010).  1907 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 79 of 82  
 47. Anderson SM et al. Multinational Home Use of Closed -Loop Control Is Safe and Effective. 1908 
Diabetes Care 39, 1143- 1150 (2016).  1909 
48. B.P. Kovatchev, E. Renard, C. Cobelli, et al. “Feasibility of outpatient fully integrated 1910 
closed -loop control: first studies of wearable artificial pancreas”, Diabetes Care, 1911 
36(7):1851 -8, 2013  1912 
49. P. Keith -Hynes, B. Mize, A. Robert and J. Place, “The diabetes assistant: a smartphone - 1913 
based system for real -time control of blood glucose”, Electronics, 3(4):609 -623, 2014  1914 
50. J. Place, A. Robert, N.B. Brahim, et al. “DiAs web monitoring: A real -time remote 1915 
monitoring system designed for artificial pancreas outpatient trials”, J. Diabetes Sci. 1916 
Technol., 7(6):1427- 1435, 2013  1917 
51. Lau, N, McElwee M, Wakeman C, DeBoer M, Chernavvsky DR, Real Time Remote 1918 
Monitoring with Artificial Panrceas: A Family -Centered Pilot Trial, Diabetes Care 63 Sup 1: 1919 
LB27, 2014  1920 
52. Gonder -Frederick L, Hughes -Karvetski C, McElwee M, Kovatchev BP, Interactive Internet 1921 
Intervention Providing Individually -Tailored Glycemic Feedback Based on CGM, Insulin 1922 
and Meal Data, and Computer Simulation: Content Design. Diabetes Technology & 1923 
Therapeutics. February 2013, 15(S1): A -104-A- 105 1924 
53. Kubiak T, Mann CG, Barnard KD and Heinemann L.  Psychosocial Aspects of Continuous 1925 
Glucose Monitoring: Connecting to the Patients’ Experience.  J Diabetes Sci Technol 2016 1926 
Jul; 10(4): 859- 863 1927 
54. Barnard KD and Weisberg -Benchell J, Psychosocial Aspects and Diabetes Technology:  1928 
Head to Head or Hand in Hand. European Endocrinology 12(1):35 January 2016  1929 
55. Friedman B, Kahn PH, Howe JR and Howe DC 2000. Trust online, Communications of the 1930 
ACM, 43, 12, 34- 40. 1931 
56. Ritholz MD, Atakov -Castillo A, Beste M, et al. Psychosocial factors associated with use of 1932 
continuous glucose monitoring. Diabet Med. 2010;27:1060 -1065  1933 
57. Lieberman A, Barnard K. Diabetes technology and the human factor. Diabetes Technology 1934 
& Therapeutics. Feb 2018.S -128-S- 138.http://doi.org/10.1089/dia.2018.2511  1935 
58. Barnard KD, Wysocki T, Thabit H, Evans M et al.  Psychosocial Aspects of Closed and Open 1936 
Loop Insulin Delivery: Closing the Loop In Adults with Type 1 Diabetes in the Home Setting  1937 
Diabetic Medicine 32(5)  January 2015  DOI: 10.1111/dme.12706  1938 
59. Kovatchev BP, Patek SD, Dassau E, Doyle FJ III, Magni L, De Nicolao G, and Cobelli C. 1939 
Control -to-range for diabetes: functionality and modular architecture, J Diabetes Sci 1940 
Technol, 3: 1058- 1065, 2009.  1941 
60. Patek SD, Magni L, Dassau E, Karvetski CH, Toffanin C, DeNicolao G, DelFaverokS, Breton 1942 
M, Dalla Man C, Renard E, Zisser H, Doyle FJ III, Cobelli C, Kovatchev BP. Modular Closed - 1943 
Loop Control of Diabetes, Transactions on Biomedical Engineering, 29: 2986 -3000, 2012.  1944 
61. Kovatchev BP, Cox DJ, Gonder -Frederick LA Young -Hyman D, Schlundt D, Clarke WL. 1945 
Assessment of risk for severe hypoglycemia among adults with IDDM: Validation of the 1946 
Low Blood Glucose Index, Diabetes Care  21: 1870- 1875, 1998.  1947 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 80 of 82  
 62. Brown SA, Jiang B, McElwee- Malloy M, Wakeman C, Breton MD. Fluctuations of 1948 
hyperglycemia and insulin sensitivity are linked to menstrual cycle phases in women with 1949 
T1DM. Journal of diabetes science and technology. 2015 Oct 14;9(6):1192 -9. 1950 
63. Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane 1951 
WV, Weinzimer SA. Effect of age of infusion site and type of rapid- acting analog on 1952 
pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving 1953 
insulin pump therapy. Diabetes Care. 2009 Feb 1;32(2):240 -4. 1954 
64. Ben Brahim N, Place J, Renard E, Breton MD. Identification of main factors explaining 1955 
glucose dynamics during and immediately after moderate exercise in patients with type 1956 
1 diabetes. Journal of diabetes science and technology. 2015 Oct 18;9(6):1185 -91. 1957 
65. Kovatchev BP. Metrics for glycaemic control - from HbA1c to continuous glucose 1958 
monitoring. Nature Reviews Endocrinology. 2017 Jul 1;13(7):425 -36. 1959 
66.  Cox, DJ, Carter, WR, Gonder- Frederick, LA, Clarke, WL, Pohl, S. Blood Glucose 1960 
Discrimination Training in Insulin -Dependent Diabetes Mellitus Patients. Biofeedback and 1961 
Self-Regulation. 1988;13(3):201- 217.  1962 
67. Cox, DJ, Gonder -Frederick, LA, Julian, D, Cryer, P, Lee, JH, Richards, FE, Clarke, WL. 1963 
Intensive Versus Standard Blood Glucose Awareness Training (BGAT) with Insulin- 1964 
Dependent Diabetes: Mechanisms and Ancillary Effects. Psychosomatic Medicine. 1965 
1991;53(4):453- 462.  1966 
68. Cox, DJ, Gonder -Frederick, LA, Julian, D, Clarke, W. Long -term Follow -up Evaluation of 1967 
Blood Glucose Awareness Training. Diabetes Care. 1994;17(1):1 -5. 1968 
69. Cox, D, Gonder -Frederick, L, Polonsky, W, Schlundt, D, Julian, D, Clarke, W. A Multicenter 1969 
Evaluation of Blood Glucose Awareness Training -II. Diabetes Care. 1995;18(4):523 -8.  1970 
70.  Gonder -Frederick LA, Julian DM, Cox DJ, Clarke WL, Carter WR. Self -measurement of 1971 
blood glucose: Accuracy of self- reported data and adherence to recommended regimen. 1972 
Diabetes Care. 1988;11(7):579- 585.  1973 
71. Gonder -Frederick LA, Cox DJ, Bobbitt SA, Pennebaker JW. Mood changes associated with 1974 
blood glucose fluctuations in insulin dependent diabetes mellitus. Health Psychology. 1975 
1989;8(1):45- 59. 1976 
72. Clarke WL, Cox DJ, Gonder- Frederick LA, Julian D, Schlundt D, Polonsky W. The 1977 
relationship between non- routine use of insulin, food and exercise and the occurrence of 1978 
hypoglycemia in adults with IDDM and varying degrees of hypoglycemic awareness and 1979 
metabolic control. Diabetes Educator. 1997;23(1):55 -58. 1980 
73. Clarke WL, Cox DJ, Gonder- Frederick LA, Julian D, Kovatchev B, Young -Hyman D. The 1981 
biopsychobehavioral model of risk of severe hypoglycemia II: Self -management 1982 
behaviors. Diabetes Care. 1999;22(4):580 -584.  1983 
74. Clarke WL, Cox DJ, Gonder -Frederick LA, Kovatchev B. Hypoglycemia and the decision to 1984 
drive a motor vehicle by persons with diabetes. JAMA. 1999;282(8):750- 4. 1985 
75. Cox DJ, Gonder -Frederick LA, Schroeder DB, Cryer PE, Clarke WL. Disruptive effects of 1986 
acute hypoglycemia on speed of cognitive and motor performance. Diabetes Care. 1987 
1993;16(10):1391 -1393.  1988 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 81 of 82  
 76. Cox DJ, Kovatchev BP, Gonder -Frederick LA, Summers K, McCall A, Grimm KJ, Clarke WL. 1989 
Relationships between hyperglycemia and cognitive performance among adults with type 1990 
1 and type 2 diabetes mellitus. Diabetes Care. 2005;28(1):71 -77. 1991 
77. Cox D, Gonder -Frederick L, McCall A, Kovatchev B, Clarke W. The effects of glucose 1992 
fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and 1993 
hyperglycaemia among adults with type 1 or type 2 diabetes. International journal of 1994 
clinical practice. Supplement. 2002;(129):20 -6. 1995 
78. Gonder -Frederick L, Zrebiec J, Bauchowitz A, Lee J, Cox D, Ritterband L, Kovatchev B, 1996 
Clarke W. Detection of hypoglycemia by children with type 1 diabetes 6 to 11 years of age 1997 
and their parents: a field study. Pediatrics. 2008;121(3):e489- 95. 1998 
79.  Gonder -Frederick , LA, Zrebiec , JF, Bauchowitz , AU, Ritterband , L, Magee , JC, Cox , DJ, 1999 
Clarke WL. Cognitive Function Is Disrupted by Both Hypo -and Hyperglycemia in School- 2000 
Aged Children With Type 1 Diabetes: A Field Study. Diabetes care. 2009;32(6):1001 -6. 2001 
80. Gonder -Frederick LA, Grabman JH, Kovatchev, B, Brown SA, Patek S, Basu A, Pinsker JE, 2002 
Kudva YC, Wakeman CA, Dassau E, Cobelli C. Is Psychological Stress a Factor for 2003 
Incorporation into Future Closed- Loop Systems? Journal of Diabetes Science and 2004 
Technology. 2016;10(3)640 -6. 2005 
81.  Gonder -Frederick LA, Grabman JH, Shepard JA, Tripathi AV, Ducar DM, McElgunn ZR. 2006 
Variability of Diabetes Alert Dog Accuracy in a Real- World Setting. Journal of Diabetes 2007 
Science and Technology. 2017;doi: 1932296816685580.  2008 
82. Gonder -Frederick LA, Grabman, JH, Shepard JS. Diabetes Alert Dogs (DADs): An 2009 
Assessment of Accuracy and Implications. Diabetes Research and Clinical Practice Volume 2010 
134, December 2017, Pages 121- 130   2011 
83. Jackson DN, & Tremblay PF. The Six- Factor Personality Questionnaire. In B. de Raad & M. 2012 
Perugini (Eds.), Big Five Assessment (p. 354 -372). Hogrefe & Huber Publishers.  2013 
84. Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, Parkin CG, Koehler Vesper I, 2014 
Petersen B, Schweitzer MA, Wagner RS. Use of an Insulin Bolus Advisor Improves Glycemic 2015 
Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal 2016 
Glycemic Control. Diabetes Care. 2013 Nov 36(11) 3613- 3619.  2017 
85. Peyrot M, Rubin RR.  Structure and Correlates of Diabetes -Specific Locus of Control. 2018 
Diabetes Care. 1994;17:994– 1001.  2019 
86. Ferraro LA, Price JH, Desmond SM, Roberts S. Development of a Diabetes Locus of Control 2020 
Scale. Psychological Reports, 1987, Volume: 61 (3) 763 -770.  2021 
87. Van Der Ven NC, Weinger K, Yi J, Pouwer F, Adèr H, Van Der Ploeg HM, Snoek FJ. The 2022 
Confidence in Diabetes Self -Care Scale: Psychometric Properties of a New Measure of 2023 
Diabetes -Specific Self -Efficacy in Dutch and US Patients with Type 1 Diabetes. Diabetes 2024 
Care. 2003;26(3):713– 718. doi:10.2337/diacare.26.3.713  2025 
88. Clarke WL, Cox DJ, Gonder- Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced 2026 
Awareness of Hypoglycemia in Adults with IDDM: A Prospective Study of Hypoglycemic 2027 
Frequency and Associated Symptoms. Diabetes Care 18:517 –522, 1995  2028 
CLINICAL PROTOCOL  
 
 
DSS- 2_05- Oct-2021   Page 82 of 82  
 89. Fisher L, Hessler DM, Polonsky WH, Mullan J. (2012).  When is Diabetes Distress Clinically 2029 
Meaningful?  Establishing Cut -Points for the Diabetes Distress Scale.  Diabetes Care, 35, 2030 
259-264.  2031 
90. Polonsky WH, Fisher L, Esarles J, Dudl RJ, Lees J, Mullan JT, Jackson R (2005). Assessing 2032 
Psychosocial Distress in Diabetes: Development of the Diabetes Distress Scale.  Diabetes 2033 
Care, 28, 626- 631.  2034 
91. Gonder -FrederickLA, Schmidt KM, Vajda KA, et al. Psychometric Properties of the 2035 
Hypoglycemia Fear Survey -ii for Adults with Type 1 Diabetes. Diabetes Care. 2036 
2011;34(4):801– 806, 2011.  2037 
92. Singh H, Gonder -Frederick L, Schmidt K, Ford D, Vajda KA, Hawley, Cox DJ.  Assessing 2038 
Hyperglycemia Avoidance in People with Type 1 Diabetes. Diabetes Management. 2039 
4(3):263 -271, 2014.  2040 
93. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality 2041 
Index: A New Instrument for Psychiatric Practice and Research. Psychiatry Res. 2042 
1988;28:193– 213. PMID: 2748771 DOI:10.1016/0165- 1781(89)90047- 4   2043 
94. Weissberg -Benchell J, Hessler D, Polonsky WH, Fisher L. Psychosocial Impact of the Bionic 2044 
Pancreas During Summer Camp. J Diabetes Sci Technol. 2016;10(4):840– 844, 2016.  2045 
95. Weissberg -Benchell J , Shapiro JB, Hood K, Laffel LM, Naranjo D, Miller K, Barnard K.  2046 
Assessing patient -reported outcomes for automated insulin delivery systems: the 2047 
psychometric properties of the INSPIRE measures.  Diabet Med. 2019 May;36(5):644 -652. 2048 
doi: 10.1111/dme.13930.  2049 